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Abstract
A new generation of protein scaffolds is becoming a valid alternative tool to recombinant
antibodies of biotechnological, medical and pharmaceutical applications, where strong affinity
and specificity are required. They share with antibodies important features (target affinity and
specificity), but they have also some improvements (smaller size of molecule, tolerance to
modification of the framework and the recognition site restricted to few residues), that can be
exploited for biosensing application in nanotechnological platforms. Nanotechnology has been
played an increasingly important role in the development of biosensors, improving the intrinsic
features of biodevices.
In this thesis work, we analyzed the coiled-coil domain, a widely spread dimerization
domain shared by several protein scaffolds, and involved in protein-protein interaction in both
eukaryotic and prokaryotic cells. The analysis of the coiled-coil structure allows a de novo
design of new peptides, namely E and K, that can dimerize as a E/K coiled-coil system: the
dimerization feature and the stability of the interaction makes this system an ideal platform to
build up functional and customizable biosensors.
A characterization of the E/K interaction was performed by using the protein
complementation assay (PCA), a useful biological method to investigate the interaction between
protein partners. With this in vivo method, we corroborate the interaction features determinate
with circular dichroism, and we demonstrated that E and K coils effectively represent a protein
scaffold, able to tolerate amino acid substitutions without altering its main structure. In addition,
we create two libraries of K mutant coils, randomizing the peptide sequence, and with PCA we
selected new K binders (Kran 5.17 and Krd F8) that showed a comparable interaction activity
with the E-coil in preliminary in vitro tests.
In the last part of this work, we generate a library of a new scaffold molecule (the single
chain E-K) capable to bind small molecules as a single protein product containing both
domains. Using the phage display selection system, we isolated scsE-K that can bind our
analyte (the caffeine) with high specificity. This new molecules can be a powerful tool for
analytical and biomedical applications.
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Riassunto
INTRODUZIONE.
La richiesta di dispositivi bioanalitici è marcatamente incrementata negli ultimi anni da parte
di diversi settori, quali ad esempio quello biomedicale (diagnostico e terapeutico), commerciale,
per il controllo ambientale e per la biodifesa. La richiesta è costantemente quella di specifici
sensori che permettano misure e analisi in maniera attendibile, veloce ed efficiente.
Le nanotecnologie hanno dato un grande contributo per sviluppo di biosensori sempre più
efficaci e in scala miniaturizzata. L’utilizzo di nuovo materiali e la scoperta di nuove proprietà
fisico-chimiche, che vengono evidenziate in nano-scala, hanno permesso lo sviluppo di
applicazioni biosensoristiche sempre più sensibili e configurabili, basate su piattaforme
nanotecnologiche: nanoparticelle magnetiche, quantum dots, nanocantilever e nanoarray hanno
trovato un ampio utilizzo, soprattutto dopo il raggiungimento di importanti obiettivi come il
sequenziamento del genoma umano e lo studio dell’intero profilo proteico (proteoma).
Alcune di queste piattaforme biosensoristiche possono essere costruite utilizzando le
proprietà d’interazione fra proteine, ad esempio fra un anticorpo e un suo antigene. Gli anticorpi
ingegnerizzati sono utilizzati in molte applicazioni, ma hanno delle limitazioni riconducibili alla
loro struttura e alle loro proprietà fisico-chimiche. Una nuova generazione di scaffold proteici ha
suscitato un grande interesse per un utilizzo come elemento sensibile in applicazioni
biotecnologiche e biosensoristiche. Queste proteine, spesso di origine naturale e coinvolte in
attività biologiche, possiedono la stessa capacità di legame ad alta affinità e specificità con una
molecole complementare, ma possiedono caratteristiche vantaggiose quali le minori dimensioni,
il sito di riconoscimento ristretto a pochi residui amminoacidici e la tolleranza alle modifiche.
La caratteristica fondamentale degli scaffold è la loro capacità di tollerare modifiche alla
sequenza, non alterando il folding della proteina risultante. Le modifiche che possono essere
apportare sono molte, e spesso volte a cambiare la specificità di legame. Considerando la
struttura, si possono apportare specifiche modifiche: per esempio, possono essere rese
accessibili delle regioni precise a degli interattori, formando vere e proprie tasche. Un aspetto
fondamentale da considerare è la struttura dello scaffold, che può presentare solo domini ad α-
elica (ad esempio, affibodies e domini a cerniere di leucine), β-foglietto (lipocaline e knottins) o
una combinazione dei due (defensine e domini PDZ).
I domini ad α-elica sono molto comuni nei sistemi di interazione proteina-proteina. Un
dominio molto comune, coinvolto in molti processi cellulari di dimerizzazione, viene chiamato
coiled-coil. Sono stati inizialmente studiati domini dimerici, formati da due eliche destrorse che
avvolgendosi formano un’unica elica sinistrorsa (es. α-cheratina); successivamente, analisi
approfondite ai raggi X hanno permesso di scoprire domini coiled-coil multimerici. Le sequenze
delle proteine che formano l’interazione hanno mostrato una presenza costante di determinati
residui amminoacidici, fondamentali per l’instaurarsi dell’interazione stessa. Residui idrofobici
formano un core apolare, fondamentale per la stabilità e per la specificità di legame, mentre
residui carichi o polari formano una regione carica esterna che guida la dimerizzazione stessa e
permette di isolare il core apolare, aumentando la forza d’interazione.
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La stessa natura aminoacidica, in termini di carica posseduta, è stata mantenuta per la
progettazione ex novo di un dimero coiled-coil, chiamato E/K. E’ un dominio costituito da due
peptidi distinti (E e K), formati da un’unica eptade ripetuta 5 volte; ognuno dei peptidi ha
un’eptade con una sequenza propria. L’interazione fra i due peptidi è stata caratterizzata a
fondo: l’elevata stabilità e affinità del sistema permettono di ipotizzare l’uso del dominio E/K
come scaffold proteico per applicazioni biosensoristiche. E’ possibile pensare di incrementare la
qualità d’interazione fra i due peptidi, permettendo un miglioramento dell’efficienza del
biosensore; inoltre è possibile creare delle nuove strutture che permettono il legame di piccole
molecole, strutture che possono essere anch’esse applicate su dei biosensori.
RISULTATI E DISCUSSIONE.
Il dominio E/K possiede delle caratteristiche adatte per un suo utilizzo in biosensoristica
come scaffold molecolare: è piccolo (costituito da 35 aminoacidi per elica), stabile e con grande
affinità e specificità di interazione. Le sue proprietà d’interazione sono state determinate
mediante metodi fisico-chimici, come il dicroismo circolare, ma nella prima parte di questo
lavoro l’interazione è stata testata mediante un sistema in vivo, ovvero il saggio di
complementazione proteica (PCA, protein complementation assay).
Sviluppato come sistema di studio delle interazioni proteina-proteina, è stato
successivamente migliorato per l’analisi del proteoma: la tecnica si basa sull’utilizzo di una
proteina reporter divisa in due domini funzionali, e prodotti in fusione con degli interattori. Il
folding della proteina reporter dai sui frammenti è catalizzata dal legame delle proteine
interattrici, e l’attività dell’enzima integro è ricostituita. Ogni proteina reporter ha un suo
specifico fenotipo rilevabile, ad esempio l’emissione di fluorescenza (GFP) o la crescita in
terreno con antibiotico (β-lattamasi). L’enzima reporter utilizzato per questo lavoro è stato la β-
lattamasi, un enzima che idrolizza l’anello β-lattamico di molte penicilline. E’ stato diviso in
due frammenti, chiamati α e ω: entrambi i frammenti sono stati espresso in batteri E. coli in
fusione con uno dei peptidi del dominio coiled-coil (E con il frammento α, K con il frammento
ω). Usando gli opportuni controlli, dall’analisi della capacità di crescita dei batteri in presenza
di ampicillina è stata determinata la qualità d’interazione fra i peptidi: questi esperimenti
preliminari hanno dimostrato come l’interazione fra E e K possa avvenire anche in un sistema in
vivo, confermando i dati ottenuti dal dicroismo circolare, e come la PCA basata sulla β-lattamasi
sia un metodo affidabile per valutare le interazioni proteina-proteina.
Lo sviluppo di un sistema basato sul dimero E/K, ma più evoluto dal punto di vista della
stabilità, è stato un altro obiettivo di questo lavoro. Migliorare la stabilità di questo dominio
proteico significa modificare opportunamente la struttura, senza intaccare il folding dell’intero
complesso: pertanto abbiamo verificato che i peptidi E e K possano essere considerati uno
scaffold proteico, ovvero che tollera cambiamenti della sequenza amminoacidica. Modifiche
alla struttura wild type sono state apportate sostituendo i residui di entrambe le catene in
specifiche posizioni nell’eptade centrale con l’aminoacido glicina: i risultati ottenuti tramite
esperimenti di PCA hanno mostrato una capacità del sistema E/K di tollerare le modifiche,
mantenendo il folding delle nuove catene, e la qualità della loro interazione. Nonostante le
sostituzioni effettuate siano state le stesse su entrambe le catene, l’elica K ha dimostrato di avere
una struttura meno sensibile alle mutazioni, esibendo una capacità di interazione anche
superiore alla coppia di coiled-coil wild type.
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Verificata la capacità di tolleranza migliore dell’elica K rispetto all’elica E, abbiamo cercato
di migliorare il sistema d’interazione, modificandone puntualmente la struttura. Esiste un
numero buon numero di lavori in letteratura che caratterizza proteine coiled-coil e le modifica
per migliorarne l’interazione con diversi scopi: la stessa strategia è stata adottata anche in questa
tesi per il dimero E/K. La PCA è stata utilizzata per vagliare due diverse librerie di interattori
con lo scopo di identificare delle varianti con una migliore stabilità e affinità di interazione.
Sono state adottate due strategie di mutagenesi, e visti i risultati preliminari tutte rivolte a
modificare la sequenza del peptide K: la modifica è stata effettuata mediante tecniche di
mutagenesi, ed è stata applicata una completa randomizzazione dell’eptade centrale (K random
coils, o Kran) e una mutagenesi razionale dell’intera elica (K rational design, o Krd),
considerando solo i residui fondamentali per la dimerizzazione del peptide e un numero ristretto
di amminoacidi per le possibili sostituzioni. Da queste librerie sono state isolate delle varianti di
K che in PCA hanno mostrato capacità di interazione con il peptide Ewt superiori all’elica Kwt;
tutti i peptidi selezionati hanno permesso ai batteri testati in PCA di sopravvivere a
concentrazioni molto elevate di antibiotico, in alcuni casi proibitive per il dimero originale.
I peptidi isolati sono stati successivamente prodotti come proteine ricombinanti e purificati,
al fine di saggiare in vitro, mediante dei test ELISA, la capacità di interazione dimostrata in
vivo. I dati raccolti con il saggio di complementazione proteica sono stati confermati, seppure
con qualche differenza dovuta probabilmente alle diverse condizioni sperimentali. I test hanno
comunque dimostrato che i peptidi K mutanti isolati sono in grado di legare con alta affinità il
peptide E wild type, ed è stata anche dimostrata l’alta specificità dell’interazione, per l’assenza
di formazione di omodimeri.
Nell’ultima parte di questo lavoro sono state costruite delle nuove strutture scaffold,
chiamate single chain E-K (scE-K), in grado di legare delle piccole molecole. Si tratta di
un’unica molecola contenente il peptide E, un linker e il peptide K; due cisteine alle estremità
del polipeptide permettono la formazione di un ponte disolfuro e di mantenere chiusa l’intera
struttura. Da una libreria di single-chain, che presentavano le eptadi centrali randomizzate in
entrambi i peptidi, sono stati selezionati dei scsE-K in grado di legare con una buona affinità
delle molecole di caffeina. La tecnica di selezione utilizzata per isolari i single chain reattivi
contro l’analita utilizzato, la caffeina, è stata il phage display: sviluppato anch’esso come
metodo di analisi delle proteine, risulta essere molto versatile per la possibilità di selezionare
peptidi con opportune caratteristiche, tra cui la capacità di legame. I cloni isolati hanno mostrato
una valida reattività contro la caffeina, e ulteriori test con il mentone (una molecola con una
struttura simile alla caffeina) hanno dimostrato la selettività dei single chain isolati nel
riconoscere la molecola di caffeina.
Pertanto, le tecniche di selezione utilizzate si sono dimostrate valide ed efficienti per valutare
le interazioni molecolari, ed isolare interattori con caratteristiche vantaggiose per un utilizzo in
biosensoristica. Sia la struttura E/K single chain, sia gli interattori mutanti K possono essere
utilizzati come elementi molecolari sensibili in nano-piattaforme come i nanoarray, e la loro
produzione può essere facilmente effettuata tramite nuove tecniche di co-trascrizione/traduzione
proteica in situ, come le tecniche PISA (protein in situ array), NAPPA (nucleic acid
programmable protein array) e DAPA (DNA array to protein array).
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Introduction
Chapter 1
Biosensors
1.1 Introduction to biosensors
The demand for bioanalytical devices has increased markedly in recent years, driven by need
in many commercial and research sectors for specific sensors that are capable of rapid, reliable
measurements [1]. Biosensors are powerful tools that are able to provide accurate detection of
target analytes; they have always been important in the fields of biomedical diagnostics (e.g.,
bacteria, virus tissue components), drug discovery, biodefense, and environmental monitoring
(e.g., air, soil, water) [2], to more straightforward analyses such as fermentation, process
monitoring, and quality control of foods and beverages [3].
Traditionally, a biosensor is defined as an analytical device which converts a biological
response into an electrical signal: biological material is directly associated with a
physicochemical transducer. Only certain substances, that are supposed to be interactors of
biological part, will also result in an optical or electrical signal of physical transducer. Today,
the term “biosensor” is used to cover sensors used to determine the concentration of molecules
and other biological parameters, even if the sensor does not utilize a biological component.
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Fig. 1.1 – Principle of function of a biosensor. The interaction between a compound in a mixture and the
biological component of the sensor is converted in a physical signal. Molecules which are not able to interact
will not produce signal [4].
The biosensing research is multidisciplinary, involving biochemistry, bioreactor science,
physical chemistry, electrochemistry and software engineering: the increasing interest for
accurate and fast identification systems allows the production of suitable platforms to detect any
type of substances.
A successful biosensor must possess at least some of the following beneficial features:
1. the biological unit onto the biosensor must be highly specific and stable under normal
storage conditions;
2. the reaction should be independent of such physical parameters as pH and temperature;
3. each component of the biosensor should have minimal pre-treatment;
4. the results should be accurate, reproducible and easy to understand;
5. if the biosensor is used for invasive monitoring in biomedical analysis, the probe must be
tiny and constructed with biocompatible materials;
6. the biosensor should be cheap, small and easy to hand; it may be used by completely no-
skilled operators, on applications of personal care, health, food and environmental
monitoring, therefore, the complete devices must be “user-friendly”
Biosensors were initially developed for clinical diagnosis, in the determination of blood
glucose or the protein concentration in biological samples [5]. In recent years, biosensors have
developed increasing sensitivity, which is an important feature, e.g., to detect tumor biomarkers
that appear at very low levels in early stages, especially when the patient is still asymptomatic,
or the disease is still in latent- or silent-stage. Some of these devices have been also
miniaturized in order to obtain a chip-based sensory system.
Nanotechnology has played an increasingly important role in the development of biosensors,
improving the intrinsic features of biodevices: the use of new material, their sub-micron size
and their important new physical proprieties at nano-level, has revolutionized the field of
chemical and biological analysis, enabling rapid and accurate analysis [6-10].
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1.2 Nanotechnology meets biosensors
Nanotechnology is the creation, the control and the utilization of material, devices and
systems through the control of nanoliter (1 bilionth of a liter) amounts of fluids as well as
control of matter on a nanometer (1 bilionth of a meter) length scale.
An important aspect of nanotechnology is that if the size of the whole system decreases, the
number of physical phenomena become pronounced, as a mechanical effects. In fact, the study
of suitable materials for nanotechnological applications is one of the most important fields of
research for these new devices: various nanostructures have been investigated to determine their
proprieties and possible applications in biosensors, and these structures include nanotubes,
nanofibers magnetic and semiconductor nanoparticles, plasmonic metallic nanostructures and
thin films [8, 11].
Some nanotechnological improvements permit the miniaturization of several systems,
materials and devices with advantages for several aims, from diagnostics to high throughput
systems, resulting from the new proprieties of nano-size materials [10]: 1) Increment of
available surface due to increased surface-volume, 2) shortened transport time of molecules by
short distance, 3) the decreased needed sample to analyze allow a high linear flow rate
acquirement, 4) in the case of arrays, almost infinite expansion of detected spot.
1.3 From life science to proteomics: the nanobiotechnology
Given the inherent nanoscale functions of the biological components of living cells, it was
inevitable that nanotechnology would be applied to the life science (nanobiotechnology).
Analyses of signaling pathways by nanotechnology techniques may provide new insights into
disease process, indentifying more efficiently new biomarkers and understanding the
mechanisms of action of drugs [12].
According to the current data, the human genome consists of about 25000 genes, and it has
been completely sequenced. Now, the attention of researches is focused on the product of these
genes: the proteins and the enzymes, that determine the cellular function and the architecture.
These set of proteins, specifically expressed by a cell under defined conditions, is the
“proteome”, for analogy with the genome [13]. In fact, the genome is a static information
because it is a constant entity of cells. On the contrary, the proteome is a dynamic information,
because it depends on the gene products and their interactions.
The proteome is a complex molecular system, and it is larger then proteome: there are more
proteins than genes, and all it depends on differential splicing of respective mRNA, temporal
and functional regulation of gene expression, formation of multimeric complexes, and post-
translational modifications. The definition of the whole human-proteome will be the challenge
of the next years, and it will be a more difficult task than the definition of the genome.
To this purpose, proteomics is playing an important role in the study of methodologies
allowing the correlation of the huge quantity of data about genes and the analysis of a larger
number of components, e.g. with throughput systems [14]. Some nanotechnologies are refining
the application of proteomics: they are providing nanofabricated devices that are small, sensitive
and less expensive (in terms of time of analysis and money) than the standard protocols,
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allowing to overcome problems respect to sensitivity, speed and the requirement of large
amounts of starting material [8, 10, 15].
1.4 Nanobiotechnological applications
Most of the nanobiotechnology application, for example, in molecular diagnostics falls under
the wide category of biochips and microarrays, more correctly termed nanochips and
nanoarrays. Currently, the advances in this field open new opportunities and provide other
powerful tools in genomics, proteomics, molecular diagnostics and high throughput screenings
[12].
To enhance the signal-to-noise ratio and to increase the features of biodevices, several types
of nanotechnologies were directly incorporated to biosensing applications. The
nanotechnologies applied to biodevices can be categorized into three potential fields (some
examples for each category) [10]:
1) technologies that involve nanoparticles (NP): gold NP, magnetic NP, bio barcodes, and
quantum dots (QDs);
2) technologies for developing nanosensors: PEBBLE sensors, electronic biosensors, SPR
sensors, nanocantilevers, nanowires and nanotubes;
3) technologies for nanochips and nanoarrays, and nanostructured surfaces for analysis via
mass spectroscopy.
In the last years, a lot of different variants of nanodevices have been developed especially for
medical purposes (viral detections [16, 17], detection of bacteria [18, 19], detection of disease
genes [20, 21], imaging [22]), but there are many potential applications in other fields.
1.4.1 Nanoparticles
The nanoparticles are the most used technologies at nano-size for diagnostics and several
biomedical applications. The particles are sized between 1 and 100 nanometers, and they are
often composed by material that at nano scale show unique and advantageous physical
proprieties (e.g., a magnetic or electronic behavior) [11, 23, 24].
The Quantum Dots (QDs) are semi-conducting crystals that show a particular optical
propriety that is absent in the bulk material: they emit fluorescent light when excited by a light
source such a laser. The size and the shape of QDs can be easily controlled by parameters used
in the synthesis [25]; the emitted spectra is wide, from ultraviolet to red, and it can be tuned by
the control of the size and the compositions of the nanoparticles. The fluorescent features make
the QDs powerful tools for several aims, from the cancer diagnosis and therapy [20] to in vivo
molecular and cellular imaging [26-29].
The surface can be functionalized with antibodies or aptamers, creating fluorescent-
immunoassay and –immunoistochemistry probes. Their use was demonstrated for long-term
multicolor imaging and to label live cells [30]. The surface is completely configurable by using
avidin: the interaction with biotinylated molecules permits a stable conjugation of the
nanoparticles with a wide range of ligands. Other experiments demonstrated that QDs – probes
can be used in an unique in vitro assay to simultaneously detect several different toxins from a
little amount of sample [31].
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Metal NPs, in particular gold, have been used to improve the performances of biosensing:
they were initially used for first Point-of-Care diagnostics, in pregnancy tests [11]. As for QDs,
the surface can be functionalized with antibodies, DNA and other ligands: recently, the electric
and magnetic features were exploited for electrical detection in arrays, by using nanoparticle
coated with DNA [32], and for a rapid screening of telomerase activity in tumor samples [33].
Gold-NP can be detected with a lot of different techniques (optical absorption, Surface Plasmon
Resonance, Raman scattering, atomic and magnetic force), make them good labels for sensors
[15, 34].
A new powerful detection system, based on metal nanoparticles, was develop to detect
specific molecules with attomolar sensitivity: the bio-barcode assay [35]. It utilizes two types of
metal particles: a magnetic microparticle coated with the recognition agent (oligonucleotides to
detect nucleic acids, antibodies to detect proteins) and a gold nanoparticle coated with the same
recognition agent and with hundred of DNA copies (the “bar-codes”) that encode for the target
of interest. When the particles both recognize the target molecule, a magnetic field is used to
separate the complexes from the solution. The DNA copies are detected with high sensitivity
detection systems, by using amplification cycles of PCR or with modified-DNA chips. The
lowest limits of detection achieved are zeptomolar (10-21) for DNA and attomolar (10-18) for
proteins.
Regarding the high sensitivity of the system, this assay can be used to reveal the low levels
of disease biomarkers in early stages, when it is still asymptomatic. It was used to detect the
presence of prostate specific antigen (PSA) in 1 ul biological sample [36], and the amyloid-
derived diffusible ligand in cerebral spinal fluids samples [37].
Fig. 1.2 – The bio-barcode assay. The assay uses a magnetic particle functionalized with antibodies, that
recognize a protein (ADDL, amyloid-β-derived diffusible ligands, in the picture). The same protein is
recognized by a nanoparticle that is functionalized with the antibodies and labeled with dsDNA. After
washing steps and the dehybridization, the specific barcode-DNA is released [37].
1.4.1 Nanosensors
The most promising devices in biosensors are the nanowires. These sensors possess the
ability to transduce a chemical binding in an electric signal: the conductance of the nanowire
change after a binding event (by protein, DNA or other ligands). The big advantage of this
nanobiosensor is the directly label-free detection signal of interaction. As nanoparticles, the
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nanowires can be coated with DNA [38] or proteins [39] to detect DNA-DNA, protein-DNA or
protein-protein interactions.
The Biodetect® system exploits the features of both nanowires and nanoparticles [40]. Two
wires are separated on an array, but they can be linked by a molecule of DNA which interacts at
the ends with the wires: then, the DNA is covered by metallic nanoparticles. The DNA
molecules form a “electrical bridge” between the wires, and the passage of the current is easily
detected. Several chips have been developed, with specific wires for different DNA target, from
the same or a different organism.
Also nanotubes can be used in electrochemical biosensors, functionalized with proteins or
nucleic acids [41]. Binding events change the electric and chemical proprieties of the nanotubes:
attomolar limits of detection were achieved [42].
A nanocantilever is a small beams, similar to those used in the atomic force microscopy to
screen biological samples for screening of genetic sequences. A label-free sensor, the
nanocantilever amplifies the absorption process of a molecule on the surface, resulting in a
measurable deflection due to changes in surface stress. The surface does not possess an intrinsic
ability to bind any molecule: wanted binding events occur only if the surface is coated with
adapt layers, antibodies, DNA probes or peptides. These nanodevices have been used to detect
PSA biomarker [43], biowarfare agents [44] and the envelope protein of HIV [45]. The
necessity to configure each cantilever allows the construction of multiplexed biochips and
arrays to detect a lot of proteins simultaneously.
Fig. 1.3 – Three examples of biosensors for the detection of small molecules: (A) nanowires functionalized
with antibodies, (B) nanowires functionalized with ssDNA, (C) nanocantilever functionalized with antibodies
Adapted from [11].
1.4.3 Nanosurfaces
The matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) is the most
used method for protein identification, exploiting organic matrixes: with the mass spectroscopy
we can analyze the profile of protein, peptides, polymers and macromolecules in biological
samples [46], and pesticides in water and food [47]. The suitable matrixes must be specific for
each type of sample, and several kind of metal and metal oxides particle have been used [48].
The MALDI-TOF was used to analyze the low molecular weight proteins (LMWPs), which
include at low concentration proteolytic fragments and potential disease biomarker [49].
The human plasma is composed by more than 300000 biomolecular species, with almost 8
orders of magnitude relative abundances; the presence of proteins at high concentration and
with high molecular weight is a limitation of this approach, because they interfere with the
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absorption of the protein at low concentration. For the analysis of these biomolecular species, an
enrichment method was developed, which permit subsequent analysis with mass spectroscopy
[50]. A silica-based nanoporous surfaces were constructed to capture LMWPs: with a size-
exclusion based method, peptides can be selected, isolated and harvested by using pores with a
estimated size about 7 nm. A similar type of nanoporous material (silica and glass beads) was
used to selectively separate proteins from biological samples, analyzing their proprieties as
disease biomarkers [51].
1.5 Micro and nanoarrays
Most of the nanotechnologies have been applied to construct useful devices for biomedical
applications, generally for the health care: the extraordinary multiplexing capability of such
devices allows to envision powerful solution also for Point-of-Care home-test, not only for
biomedical aims but also for every field in which a cheaper, fast and sensitive test is needed.
Regarding this purpose, the micro- and nano-arrays are the most promising tools.
The nanoarrays are the next stage in the evolution of the miniaturization of microarrays, but
the basics are the same: to immobilize molecules at defined locations on a surface with
micrometer or nanometer resolution. Currently, the molecular resolution on the surfaces of the
arrays is higher than that of the first devices: the first protein array was described by Fodor and
his coworkers [52], developed with a light-directed synthesis and composed by 1024 protein
spots. New printing mechanisms allow to print 55000 molecules or nanoparticles on 1 cm2 area
[53].
Basically, the construction methods of micro- or nano-arrays are similar: the molecule (e.g.
nucleic acids or proteins) must be immobilized on the surface. The deposition and the
absorption is made by selecting adapt materials for the surfaces. The proteins, instead of nucleic
acids, are chemically more variable; therefore, the necessity to choose the appropriate substrate
for the application is required by users [54, 55] and by picking very small amount of samples
(picoliters). The array can be often coated with a thin layer of chemical compounds (gold, glass,
silicon), to facilitate the absorption of different inorganic or organic molecular species.
The last findings on array printing permit to obtain devices with resolution of about 100
nanometers or less, and positional accuracy of 1.5 nm [56]. With the positive-charged tip of
scanning tunneling microscope (STM), DNA molecules were picked and immobilized on a
surface, obtaining arrays with high resolution. Other commons micro patterning techniques are
photolitografy, electrospray, ink-jet printing and microcontact printing. The last mentioned
technique is very powerful method for surface structuring, useful to deposit unlimited patterns
and to print simultaneously different kind of biomolecular species. Currently, the dip-pen
nanolithography is the printing technique which deposits molecules with the highest resolution
[53].
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Fig. 1.4 – Schematic representation of an array slide printed with different types of proteins, and common
reagents used for the array analysis.
About the detection of interaction onto the arrays, the system is completely configurable, by
using fluorescent (fluorochromes Cy3 and Cy5), chemioluminescent (alkaline phosphatase and
horseradish peroxidase) and electrochemical readout systems [57]. Fluorescence is preferred for
the high sensitivity and dynamic range: the area of the array is excited by a laser beam to
fluoresce line-by-line [58]. Recently, some label-free readout systems have also been developed
[59], as ViriChip™ System, a virus detection platform based on an optimized atomic force
microscope [60]. These platforms do not need secondary reporter systems, which sometimes
can interfere with the assay.
1.6 In situ methods for protein arraying
A huge quantity of data is now available, after the completion of the human genome
sequencing: since proteins rather than DNA carry out the biomolecular functions, there is large
of interest to analyze proteins and their entirely, the proteome. The protein array was developed
and applied in some fields of applications, such as the characterization of protein-protein
interactions [61], the high-throughput screening of cellular processes and pathways [62], the
drug discovery research [63], the investigation of potential diagnostic markers in bacterial [64]
and autoimmune diseases [65].
Several recent progresses have been developed especially for nucleic acid printing onto the
arrays, with lithographic methods, as yet explained in the previous paragraph. For the protein
arraying, there is some drawback:
1) expression clones must be generated, and the soluble proteins must be expressed and
purified, to be subsequently attached onto suitable surfaces. Human or recombinant
proteins can be poorly expressed in bacterial system for insolubility, disulphide bonds
forming, degradation or toxicity in cellular hosts. Often, proteins sequences must be sub-
clones into an expression system, and all processes are time- and cost-intensive.
2) proteins, rather than DNA, are more involved in degradation events because they are
chemically more heterogeneous: therefore, the long-term storage of printed proteins and
the integrity of the arrays may be difficult to maintain in a functional state over long
periods of time.
Some improvements have been applied to overcome these drawbacks: protein arrays are
rapidly generated in one step by using cell-free lysate as in situ production method. The basic
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idea is to use cell lysate as a coupled transcription/translation system, that allow the production
and direct immobilization of any protein onto a functionalized surface. Currently, three different
systems utilize this process: protein in situ array (PISA), nucleic acid programmable protein
array (NAPPA), puromycin-capture from mRNA arrays and DNA array to protein array
(DAPA).
1.6.1 Protein in situ array (PISA)
Originally described by He and Taussing [66-69] to generate proteins array from PCR DNA,
the method is also knew as DiscernArray™ technology [67]. The proteins are generally
produced from PCR products, which include T7 promoter and sequences for in vitro
transcription/translation procedure, included a tag sequence for immobilization (Figure 1.5).
The key feature of the system is the presence of a tag at the C- or N-term of the expressed
protein sequence: the tag interact with an immobilization agent, pre-coated onto the surface of
the array. If the protein are His-tagged, the surface must be Ni-NTA (nickel nitrilo-triacetic
acid) or Ni-beads coated: when the PCR fragments are translated by using rabbit reticulocyte or
E. coli S30 system, the proteins can specifically and rapidly interact with the Ni-surface.
In recent works, some improved double and triple His tags were used to bind the GFP
(green fluorescent protein) and antibodies to pre-treated surfaces [70, 71], but also other
interaction-systems can be used (e.g. biotin-streptavidin).
Fig. 1.5 – Schematic of PISA process. (A) The PCR fragments and cell-free lysate are co-arrayed on the slide
surface, pre-coated with an immobilizing agent. (B) The proteins are transcripted and translated by the
components of the lysate, fused with a tag peptide, that can bind the immobilizing agent. (C) Extensive
washes clean the slide: the tag-proteins remain immobilized on the array. Adapted from [69].
1.6.2 Nucleic acid programmable protein array (NAPPA)
In the PISA system, PCR fragments and cell-free lysate are co-arrayed onto the pre-coated
surface. The NAPPA method provide for the DNA immobilization onto the array, developing a
technology for a directly “DNA-protein” array conversion from the same DNA pre-coated
surface [69, 72].
Biotinylated plasmids, encoding for a recombinant protein in fusion with GST, and anti-GST
antibodies are printed onto an APTES (aminopropyltrimethoxysilane) slide (figure 1.6). When
the cell-free lysate is added, the proteins are translated from the plasmids: the GST tag is
recognized by the antibody, and the protein is blocked near the encoding-plasmid, generating a
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spot array with a DNA-protein co-localization. In the first experiment a 512 spot slide was
generated, and each spot was spaced about 0,9 mm, containing an average of 675 pg of protein
[73]. In a recent work, the entire genome of bacterium Vibrio cholerae was analyzed: about
3880 open reading frames were captured onto the array [74].
As for PISA, the method does not need an external production, purification and printing of
proteins; moreover, it is possible to generate an immobilized “ready-to-use” DNA array, which
can be produced, stored and used as required. Therefore, there are some drawbacks:
- the proteins must sub-cloned into the plasmid that carries the GST sequence,
- and plasmids need to be biotinylated, preventing as far as possible the dissociation from
the array and the lateral diffusion.
- the produced array is not “pure”, because some molecules are printed: biotinylated
plasmids, streptavidin, GST-proteins and antibodies. That may cause lower sensitivity
and specificity.
In a recent work it has been demonstrated the directly absorption of DNA (cDNA or PCR
fragments) onto amine-coated glass surfaces [72]: the positively charged amine bind the DNA,
avoiding the biotinylation step.
The need for antibody as capture system for the expressed proteins was overcome in a
system where only the expression vector is arrayed [75]. In this method, the plasmid directs the
synthesis of the proteins and at the same time it is the capture agent. An high-affinity binding
(3-7x10-13 M) was exploited: the binding between the E. coli protein Tus to Ter sequence, a 20
bp sequence involved in replication processes of bacteria. The proteins of interest are
synthesized as Tus fusion proteins with a standard coupled transcription/translation, and they
interact with Ter sequence, embedded in the vector.
Fig. 1.6 – Schematic of NAPPA process. (A) The surface of the array is pre-coated with avidin, the
biotynilated plasmid and the antibody anti-tag (e.g. GST). (B) The array is entirely covered with the cell-free
lysate, and (C) the components of lysate transcript and translate the gene embedded into the plasmid. The
antibody binds the tag expressed in fusion with the protein, and D) after extensive washes the array is ready.
Adapted from [69].
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1.6.3 Puromycin-capture from mRNA array
Tao and Zhu [76] described a new strategy to obtain protein arrays, avoiding the problem of
local diffusion of the just produced protein.
The PCR products are retro-transcribed in mRNA, and they are linked with a biotinylated-
ssDNA, modified with puromycin. The mRNAs are arrayed onto the surface of streptavidin-
coated slides; the ribosomes contained in the cell-free lysate translate them. When the ribosome
reaches puromycin, the nascent polypeptide is capture by the puromcycin itself; the RNA is
removed by using the RNAse, leaving a pure-protein array.
1.6.4 DNA array to protein array (DAPA)
Every array fabricated with one of the previously explained techniques can be used only for
one experiment: the DAPA system allow the “on-demand” printing of multiple protein arrays
from a single DNA array, as required [68].
PCR fragments are covalently immobilized onto a slide that is assembled with a second
slide, coated with a tag-capturing substrate. A permeable membrane carrying a cell-free lysate is
inserted between the two surfaces: the tagged-proteins are translated from the immobilized
DNA, and quickly captured by the second slide. A protein array is created corresponding to the
DNA array. The effectiveness of the method was demonstrated by producing 20 times a protein
array of His-tagged GFP or single-chain antibodies, on Ni-NTA-coated slides: all proteins
retained the protein proprieties (fluorescence for GFP, binding activity for single-chains).
The method must be improved for the drawback of protein diffusion, but the possibility to
generate repeated pure-protein arrays from one DNA array template is a considerable
advantage.
Fig. 1.7 – The DNA is spotted and immobilized onto a glass slide. Simultaneously, a second slide is coated
with a protein-capture reagent. The slides are then assembled face-to-face with a membrane soaked with cell-
free lysate. The proteins are transcripted and translated, and the newly-synthesized tagged-protein are
captured and immobilized onto the second slide Adapted from [68]
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Chapter 2
Protein scaffolds
2.1 What are scaffolds?
Currently, the antibodies are the most important and useful binding molecules in a wide
range of biotechnological, medical and pharmaceutical applications. This success can be
ascribed to the fact that the immune system was the only source for scaffold molecules with a
huge diversity, that can interact with other molecules with high specificity and affinity. The
antibody engineering allowed to modify their structure, dissecting in minimal binding fragments
and enhancing the clinical efficiency for disease treatment [77]. However, immunoglobulins
showed some limitations, based on biophysical proprieties and their structure: the whole IgG
molecule needs to form disulfide bonds, which can limit the activity of the antibody in non-
appropriate conditions. Smaller antibody fragments were used for both therapeutic and non-
therapeutic applications, but the fragments tend to aggregate and to degrade. Moreover, some of
these antibody domain must be expressed in eukaryotic cells because they fold poorly in
bacteria: therefore, additional purification steps are required.
These drawbacks have been overcome by developing a new generation of protein scaffolds.
They possess the same features of antibodies (target affinity and specificity), but with some
improvements: smaller size of molecule, improved stability and the recognition site restricted to
few residues [78, 79]. There are some definitions to generally describe a scaffold, but we can
define it as “a protein framework that can carry altered amino acids or sequence insertion, that
confer on protein variants different functions, usually for binding specific targets” [80]. A
fundamental feature of scaffolds is that the native protein folding is not altered by the insertion
of residues in the sequence of the protein.
Most of these are involved in natural binding events and have various origins, frameworks
and functions. Original peptides can be structural proteins, sub-unit peptides from a multimeric
structure and also enzymes [81], but it is also possible to design de novo structures [82, 83].
Non-immunoglobulinic scaffolds should improve some features respect to antibodies, also if
affinity proprieties for binding targets are comparable: improving features don’t compromise
target affinity and specificity.
Modified scaffolds can be selected with in vitro and in vivo technique, isolating new
molecules with better affinity against specific ligand [84]. There are different types of natural
scaffolds that can be considered to modify, but several issues regarding the proprieties of a
candidate protein should be considered before starting selection, in particular the structure, the
topology and the size of the scaffold in conjunction with the intended modification strategy will
be of concern [85]. These selected binding reagents may become tools which can be used in a
wide range of biotechnological and biomedical application, like affinity purification [86],
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protein microarray technology [87], bio-imaging [88], enzyme inhibition [89] and targeted drug
delivery [90].
On the protein surface there are exposed loops that facilitate the binding activities; the loops
link structural elements like α-helices and β-sheets of the scaffold. Not only the loops permit the
binding activity with the ligand, but also the α-helices [91] and internal cavities [92]. However
loops are the most accessible scaffold region for modification of the sequence, for grafting or
integrating an affinity function onto or into the structural framework, without changing the
overall structure affinity of the protein and generating a stable folded protein. The following
figure shows possible modifications.
Fig. 1.8 – Engineering strategies to modify the binding site of protein scaffolds. The binding sire has been
altered, introducing the diversification with suitable strategies, as the randomization of specific domains (a, B,
c, d). A random sequence has been inserted into the scaffold (e), or modified by error-prone PCR (f).
Moreover, pre-existing binding sites can be grafted into a novel scaffold (g), or the binding site can be de-
novo designed (h) [84].
It is important to choose carefully the residues to be randomized because some modifications
may cause missfolding or instability of the scaffold itself [91].
Protein scaffolds can be characterized by several features, i.g. the presence of disulfide
bonds or presence of enzymatic activity. Based on the architecture of their backbone, they can
be assigned to one of these groups:
 scaffolds with α-helices;
 scaffolds with β-sheets;
 small scaffolds with few secondary structures or with an irregular architecture of α-
helices and β-sheets.
2.1.1 Scaffolds with α-helical domains
Although helical coiled coils belong to the most abundant structural protein motifs, the number
of library display scaffolds based on an α-helix architecture is limited compared to the
numerous examples for β-sheet frameworks.
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Nevertheless in the past years several α-helices scaffolds have been applied for libraries
construction and for interaction validation.
AFFIBODIES: first non-β-sheet proteins used for libraries constructions [93], affibodies are
small proteins derived from an engineered version (Z domain) of the five stable
three α-helices bundle domains from the immunoglobulin Fc-binding region of
staphylococcal protein A [94]. These scaffolds are soluble, proteolytically and
thermally stable and does not contain disulfide bonds. They have been used for
construction of phage libraries and selection against several proteins and
enzymes, like Taq DNA polymerase, human insulin and human apolipoprotein.
The small dimension and the strong protein structure are fundamental proprieties
of these molecules for a broad range of biotechnologies applications: affibodies
have been described for purification, detection and targeting, also suggesting the
therapeutic/diagnostic potential of this protein scaffold [87].
REPEAT PROTEINS: the main members of this category are proteins with ankyrin repeat
domains. These domains are one of the most well-studied and common modular
protein-protein interaction motifs; the ankyrin repeat is a 33-residue motif in
proteins consisting of two alpha helices separated by loops. They appear in
bacterial, archaeal, and eukaryotic proteins, but are far more common in
eukaryotes.
Designed ankyrin repeat proteins (DARPins) [95] are versatile binding proteins
which display great advantages over other binding protein. These repeat-motifs
protein offer an advantage for libraries construction because the binding interface
depends on the number of randomized repeats. In a recent application libraries of
ankyrin repeat proteins have been used to select high affinity inhibitors of
aminoglycoside phosphotransferase (3’)-IIIa (APH) [96]. The selected proteins
showed the great DARPins ability for modulation of intracellular enzyme
activity, with implication for therapeutic applications.
GCN4: GCN4, a basic leucine-zipper protein, is the primary regulator of the transcriptional
pathway of amino acid synthesis. It binds specifically to the promoters of amino
acid biosynthetic genes. As most proteins that bind DNA, GCN4 contain a
leucine zipper sequence to bind and activate genes [97].
This is the well-studied coiled-coil protein for roles of trigger sequences in
coiled-coil folding. The GCN4 α-helices interact, allowing the protein folding and
monomers dimerization. Several libraries has been constructed to evaluating
relevance of residues in the sequence.
Other examples of α-helix scaffolds are immunity proteins and the cytochrome b562.
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Fig. 1.9 – (A) Molecular model of a DARPin: the side-chains of randomized residues are labeled in red. (B)
Molecular model of the single domain. (C) The dimerization region of the transcription factor GCN4 bound
to DNA.
2.1.2 Scaffolds with β-sheet domains
Antibodies are indisputably the most characterized β-sheet protein with binding proprieties. The
specificity is mediated through complementary determining regions (CDR), hypervariable loop
regions that mediate binding to the antigen.
Immunoglobulins can bind proteins, sugars and diverse small proteins, but there are some
limitations for biotechnology applications, for example due to the dimensions of antibodies.
These are motivations to find alternative binding molecule.
KNOTTINS: knottins are small disulfide-rich proteins characterized by a special “disulfide
through disulfide knot”. The knottin motif is found in some plant-protease
inhibitors, toxins and antimicrobial peptides. A typical “knotted topology” unit
consist in a small triple-stranded β-sheet with at least 3 disulfuide bridges and
interspersed variable peptide loops.
Residues in the loops can be mutagenized, and with affinity selection methods a
better binding activity can be obtained [98]. In effect the knot proteins are an
attractive scaffold for drug design, and they have been considered a good starting
point for grafting recognition sites or active sites onto it for the production of the
new bioactive molecules [99].
LIPOCALINS: the lipocalins are a family of proteins which transport small hydrophobic
molecules such as steroids, bilins, retinoids, and lipids. They are 160- to 180-
residues polypeptides that share common tertiary structure architecture,
consisting in a beta-barrel of six-or eight anti-parallel β-strands, connected by
four hyper-variable loops.
The conical structure encloses an internal ligand binding site which is ideal to
randomize residues, allowing the generation of new protein binders with high
affinity and specificity. Some new binders have been isolated from a bilin-
binding-protein library and selected against fluorescein and digoxigenin with
nanomolar Kd [78].
Other examples of β-sheet proteins are neocarzinostatins, T-cell receptors, 10th fibronectin type
III domain, CTLA-4 and green fluorescent protein.
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Fig 1.10 – (A) Molecular model of a typical knottin motif: this domain is also termed CSB (Cystine
Stabilized β-sheet) disulfide bridges. (B) A typical “knotted topology” consists in a small triple-stranded β-
sheet with 3 disulfuide bridges. (C) Molecular model of a lipocalin, with the beta-barrel tertiary structure
composed by anti-parallel β-strands.
2.1.3 Scaffolds with irregular secondary structures
In this group there are some proteins that fold in structures with α-helices and β-sheets.
DEFENSINS: defensins are small (15-20 residue) cysteine-rich cationic proteins found in both
vertebrates and invertebrates, they play important roles against invading microbes
(bacteria, fungi and viruses). The group comprises proteins with an irregular
architecture of α-coils and β-sheets, or proteins with few secondary structures.
Insect defensin A has been proposed like a new scaffold for the construction of a
mutants peptide library: a total of seven residues were randomized within the two
loops of the peptide [100]. The library was screened against tumor necrosis factor
A, TNF receptor 1 and TNF receptor 2.
KUNITZ DOMAIN INHIBITORS: they are a group of small and irregular proteins of about
60 amino acids, stabilized by three disulfide bonds. They act as reversible
inhibitors of serine proteases.
They possess high stability and, most important for library generation, a loop that
can be mutated without destabilizing the structural folding. Therefore, they have
been used for modeling specificity to novel protease targets and entered clinical
trials [101].
Other scaffolds in this category are plant homeodomain (PHD) finger protein, PDZ domains,
charybdotoxins and TEM-1 β-lactamase.
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Fig 1.11 – (A) Three-dimensional structure of insect defensin A. (B) Three-dimensional model of the
catalytic domain of coagulation factor XI in complex with kunitz protease inhibitor domain of protease nexin
II.
2.2 Coiled-coil domains
In the previous paragraph, several protein scaffold were listed and described, with particular
attention for library construction and selection against various molecules. All these scaffolds
presents α-helices or β-sheets in the secondary polypeptide structure. The presence of these
secondary structures is important for protein folding and function (ex. enzyme activity, binding
function, etc). The α-helix domain is involved in the folding of another important protein
structure: the coiled-coil domain [102].
The coiled-coil is an oligomerization domain found in a wide variety of protein, including
transcription factors, virus proteins and fibrous proteins (keratin, myosin, fibrinogen). Several
surveys of genomic data bases suggest that up to 10% of eukaryotic proteins contain sequences
predicted to be coiled-coils [103], confirming that they are the most common domain for
interaction and dimerization. Despite their abundance, similarity in sequence and simple domain
structure, they are highly specific, enabling them to form fine-tuned networks of homo- and
heterotypic interactions.
2.2.1 The structure
Francis Crick was the first that proposed in 1952 the possibility of coiled coil architecture for
α-keratin [104], suggested in 1951 by Linus Pauling and co-workers [105].
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Fig. 1.12 – (A) Helical wheel representation of an heterodimeric coiled-coil domain, viewed from the N-
terminus: the fundamental residue for the interaction are highlighted. The hydrophobic residues in positions
a, d, a’ and d’ interact, allowing the formation of the apolar core; charged or polar residues in positions e, g,
e’and g’ permit the formation of potential ionic or electrostatic interchain interaction. (B) Two different views
of a coiled-coil molecular model. Adapted from [106].
It is a structure composed by two amphypatic and right-handed α-helices that usually adopt a
left-handed super-coil. The first protein described with this domain was tropomiosin: the
analysis of its sequence revealed a repeated seven amino acid residue pattern called heptad
repeats.
The structural features of coiled-coil have been reviewed extensively: their sequence is
characterized by heptad, denoted “a-b-c-d-e-f-g” and shows a heptad repeat in the chemical
nature of side chains. Positions a e d are occupied by hydrophobic residues and are important
for interhelical contacts, which contribute to the largest part of the interaction surface.
Typically, polar or charged amino acids occupy the e and g positions and aid in driving stability
and specificity by increasing the solubility of the protein. Furthermore, these e/g edge position
can shield the hydrophobic core from aqueous surroundings. The characteristic hydrophobic
repeat is strongly maintained, it is a fundamental feature for structural reasons, for folding and
stability of the protein [97].
2.2.2 The hydrophobic core
The analysis of several natural and designed coiled-coils showed the relevance of apolar
amino acids in the core: in de novo designed peptides, leucine and isoleucine in a and d position
showed better stability [107-109]. d position is typically leucine or alanine, contributing to
dimerization stability but not to specificity [110]. In contrast the a position is more variable
(always with apolar residues) and, thus, may contribute to both dimerization stability and
specificity. In the context of the GCN4 leucine zipper sequence, ideal dimmers contain leucine
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at the d, isoleucine at the a, and a single a-position with asparagine [111, 112] which can form a
buried, interhelical hydrogen bond.
The amino acid variability can be explained by side-chain residues orientation relative to the
axis formed by two α-helices (for multi-stranded coiled-coils, variability is less clear). The side-
chains of a residues point towards the external super-coil surface, favoring β-branched residues
for tight packing (ex. isoleucine, valine). The side-chains of d residues point straight away the
hydrophobic interface, favoring unbranched amino acids [113, 114].
The characteristic packing of the hydrophobic core was first described as “knob-into-holes”
packing by Crick [104].
Fig. 1.13 – Schematic representation of “knob.into-hole” model proposed by Crick for two parallel right-
handed helices.
The hallmark of coiled-coils is the distinctive packing of amino acids side-chains in the core
of the bundle, in which a residue from one helix (knob) packs into a space surrounded by four
side-chains of the facing helix. If in the a/d position there are big residues, they can not permit
correct packing required in the core; if the amino acids are polar or charged, they can destabilize
the entire super-coiled structure [108]. Therefore it is possible to modulate the matching of two
helices with local destabilization by polar or charged residue, also allowing formation of
internal cavities as a scaffold for small molecules [108, 112, 115].
2.2.3 Electrostatic interaction
The hydrophobic effect is accepted as a major driving force in protein interaction and folding
of coiled-coils. Ionic interactions and other polar interactions are destabilizing or contribute
little to protein folding [116, 117]. It is widely believed that charged and neutral polar side-
chains play a significant role in conferring conformational specificity on protein folding and
dimerization. It is clear that the charged residues of proteins are arranged so that attractions
between opposite charges are favored over interactions between like charged.
Electrostatic interactions contribute in different ways in terms of stability for each
considered coiled-coil protein, and this is due to the chemical characteristics of environment
where protein folding takes place. Interactions directly exposed to the external surface, and so in
Introduction
28
contact with solvent, are weak and they don’t add stability to the protein, whereas interactions
that take place in a protect surface contribute with a strong effect to structure stability [113].
In the coiled-coils the e and g position in the heptad repeat lie alongside the hydrophobic
core and often contains charged side-chains, which have long been predicted to participate in
interhelical interactions. The interactions also permit to isolate the core from the solvent,
stabilizing the folding of the entire structure. They also play an important role specifying homo-
and hetero-association in native proteins [118]. Some studies have shown that the balance
between g-e’ attraction (e’ is e position of second helix) and repulsion may be critical for
specifying home versus hetero-oligomerization [113, 115, 118, 119].
In addition to inter-helical interactions, the coiled-coil can be stabilized by intra-helical
interactions between charged residues [118]. The length of side-chains in residue in e/g
positions is an other important feature of the coiled-coil: there is no clear optimal total chain
length but some works show the capability to tune dimer stability with specific residues, also
with unnatural side-chains [115].
2.2.4 Number of helices, orientation and oligomerization
We described features of coiled-coil with two α-helices that form a super-coil dimer, but
natural proteins with coiled-coil domains can be interact as dimers, trimers, tetramers, and also
more complicated structures like tubes (tetrabrachion [120]), sheets (Small Conductance
Potassium Channel [121]), spirals (flagellin [122]), funnels (bacteriophage Φ29 [123]) and rings
(Apolipoprotein A-I [124]).
The oligomeric state of coiled-coil is determined by packing interactions, and thus depends
primarily on the nature of residues in positions a, d, e and g. The geometry of side-chains in
positions a and d differs systemically between two-, three, and four-stranded coiled-coils [108,
125]. In experiments with protein GCN4, Harbury showed that the structure can be switched
between two-, three-, four-stranded stases by changes of residues in hydrophobic core [126].
Much less is know about the role of residues in positions e and g in specifying oligomer
state, but ionic and polar interactions between residues in these positions are determinant for
orientation (parallel or anti-parallel) and preference for homo- and hetero-oligomeric association
of helices. Most interactions occur between residues in g of one heptad and e of the next heptad;
interactions between e/g residues of the same heptad are often prevented by the shape of the
core. Opposite e/g’-e’/g charges in two facing heptads are often necessary for the formation of
stable heterodimeric coiled-coils, but the effect of charged pairs depends on sequence context,
as Arndt and colleagues showed [106]. They isolated a stable peptide that contains two
repulsive e/g interaction from a coiled-coil library. It is clear that coiled-coil stability is
provided by number of heptads, hydrophobicity of the core, tightness of the core packing,
shielding of the core from solvent and favorable polar and ionic interactions [108, 127].
It is not yet possible to systemically predict the structure that form, or the changes in
structure that occur after modification of the protein sequence. Predicting structures is
complicated by an enormous diversity of possible topologies. Coiled-coil structures are not
determined by simple rules for hydrophobic packing and electrostatic interactions. They can
react to various stimuli. Ambroggio and coworkers designed a sequence that form a coiled-coil
homotrimer which switch to a zinc finger in the presence of ion metals [128]. Some peptides
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form coiled-coil fibers only with specific conditions of pH or temperature, or simply when
monomers are mixed [129]. Some softwares are available to predict and identify a coiled-coil
structure from a sequence, like Coils, ParCoil, MultiCoil and MarCoil [130-132]. With a protein
sequence database and residue probabilities, they analyze the sequence and predict the structure
with high sensitivity and specificity. In a recent work, some of these softwares has been
compared to predict coiled-coil motifs, evaluating the detecting accuracy of everyone [133].
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Chapter 3
E/K: a de novo designed coiled-coil
3.1 Introduction
Coiled-coil peptides have been used in numerous applications, including affinity
purification, direct assembly of extracellular receptor domains, creation of miniaturized
antibodies, microarrays and peptide libraries [134].
Already in 1993 O'Shea et al. described the design of two peptides that are predominantly
unfolded in isolation but, when mixed, they preferentially associate to form a stable, parallel,
coiled-coil heterodimer [83]. They chose peptide sequences that would be predicted to give
destabilizing electrostatic interactions in the homodimers that would be relieved in the
heterodimer.
Based on typical coiled-coil features described above, in 1996 Chao and Tripet.
characterized E/K, a de novo heterodimeric coiled-coil domain, for biosensor-based affinity and
chromatographic applications [114, 135, 136]. They analyzed the structure of several natural
coiled-coils, and some requirements were established to permit the correct folding of the new
protein [137]:
 to select amino acids that are non-disruptive for the helical structure;
 the placement of non-polar residues in positions a and d for tightest packing in the
hydrophobic core;
 to chose appropriately polar or charged residues in positions e and g that will promote
the helices associations (heterodimeric form) [138];
 the inclusion of polar or charged residues in position f, to permit the protein
solubilization in aqueous solution;
 the polar or charged residue in position f must be opposite charge respect to amino acids
in position e and g, to balance the total charge on individual α-helices;
 to select an optimal length of α-helices to permit the protein production with synthetic
means, and to avoid alteration of structure or stability of coiled-coil [139];
 balance between stability of hydrophobic core (that permit homodimer folding) and
electrostatic repulsion (that prevent the assembly of homodimers)
Several designed peptides were considered before selecting the E/K as the best coiled-coil
protein for biological application.
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3.2 The structure
The E/K coiled-coil is a new domain made of two distinct peptides, E and K: each peptide is
composed by an unique heptad repeated five times. The heptad sequence of helix E is E-V-S-A-
L-E-K (position g-a-b-c-d-e-f), and the sequence of helix K is K-V-S-A-L-K-E.
Fig. 1.14 – Helical wheel representation of E/K coiled-coil system, viewed from the N-terminus. Two right-
handed helices (E and K) interact as an unique heterodimeric supercoil, and each coil with an unique five-
times repeating heptad sequence. The hydrophobic residues valine and leucine interact in the apolar core, and
they are mainly responsible for the folding and the stability of the coiled-coil. The charged residues glutamate
and lysine contribute to the stability of the structure with interchain interactions, that shield the apolar core
from the solvent and specify the heterodimerization of the coils [114].
Neither peptide adopted significant structure on its own, in fact E or K in solution are not
correctly folded as a α-helix: circular dichroism analysis show that they exhibit a random coil
spectra [114]. In contrast, a solution containing both peptides shows typical spectra of a helical
structure: probably, peptides fold and interact as an unique super-coil protein only when they
are co-present. They associate as a heterodimeric protein of 70 amino acids, with a molecular
mass of 7682 Da. Each peptide is amidated and acetylated at the C and N termini, respectively,
to increase the propensity to helix-forming and to reduce the likelihood of proteolysis.
For the hydrophobic core, the choice was valine for position a and leucine for position d.
These β-branched amino acids are commonly found in natural and synthetic coiled-coil
peptides; for the packing geometry of side-chains, coiled-coils with these residues tend to favor
the dimeric parallel conformation [108, 134, 140]. Also if a core of valine/leucine is less stable
than a all-leucine core (or a leucine/isoleucine core), the association in unwanted structure and
high order aggregates is avoided [113, 126].
For the e and g positions, the select residues are glutamate and lysine: these are logical
candidates because they frequently occupy these positions in natural coiled-coils [141]. They
can also form favorable e/g’ interhelical salt bridges [140]. In addition, at neutral pH, the
repulsive interaction between the charged side-chains discourage formation of homodimeric E/E
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and K/K coiled-coils, promoting formation of heterodimeric E/K [108, 140, 142, 143].
Moreover, the interactions also permit to isolate the core from the solvent, stabilizing the
folding of the entire structure. Alanine was chosen for position c for its high intrinsic helical
propensity, serine was introduced into position b to increase peptide solubility, and glutamate
(K-coil) or lysine (E-coil) was introduced into position f to balance the total charge.
3.3 Characterization of dimeric E/K coiled-coil
Several coiled-coil structure exist yet in nature, but they can’t be used for biotechnological
application because these proteins present some drawbacks:
- low dimerization affinity: the natural α-helices dimerize with an affinity around 105-108;
- low dimerization specificity: natural proteins hardly present only one interactor;
- low stability in non-physiological condition: proteins could be degrade.
Main features of de novo designed coiled-coil proteins (like E/K) are high stability in
denaturant conditions and with different pH values [135, 144]. Stability of this structure was
studied with chemical and temperature denaturation experiments, monitored with CD
spectroscopy [108, 135].
It is resistant to heat denaturation up to 85°C, and with 5M denaturant conditions. Also
combination of 85°C and urea 5M is unable to denature the protein. Currently only guanidine
HCl 3,9 M can denaturate the E/K coiled-coil. This high association strength is highlighted by
the affinity constant for this dimer: 63 picomolar [145].
Fig. 1.15 – The graph resumes the denaturation experiments with urea ( ), GdnHCl( ) and temperature ( ).
Guanidine HCl is the only agent which can completely denaturate the E/K folding [114].
The ability to remain stable was tested also in biological medium, like human serum. E and
K single peptides and folded dimer E/K were incubated for 50 h at 37°C with non significant
degradation .
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3.4 E/K applications
The high stability and fast association and slow dissociation kinetic make E/K an ideal
protein for biological applications, that require a stable dimerization and capture domain. In an
ideal biosensor applications, one of two α-helices is covalently immobilized on the surface
sensor. The second peptide is conjugated with whatever protein, like antibodies, and injected
over the sensor surface. The interaction of anchored peptide and fused protein generates an
antibody surface for biosensing. In this way the surface is completely configurable with any
combination of interactors, choosing the correct “fused” peptide. The sensor surface so
assembled can be reused repeatedly as long as it is charged with a sufficient amount of the
coiled-coil conjugated.
An example of this application is a particular type of nanoarray, named Nano-Capture Kcoil,
developed by Plexera Bioscience. K α-helix can be covalently linked with disulfide bond on the
surface, which is coated with a thin gold layer. Then, the array can be charged with the E-coil,
conjugated with suitable interactor (protein A, protein G, antibodies, ecc) for the biosensor
applications.
Fig. 1.16 – Examples of E/K applications. (A) K-coils are immobilized with thiol bonds onto a glass slide, pre-coated
with a gold layer. E-coil-fusion proteins are injected over the slide surface, and, exploiting the E/K dimerization
proprieties, the slide is functionalized with any desirable protein. (B) The surface can be also functionalized with
antibodies fused with the E-coil, for antigen-binding biosensing platforms [114].
The versatility of the E/K heterodimeric coiled-coil as a dimerization and capture domain led
us to explore the possibility of using this protein as an affinity purification tag [136]. E/K can be
used 1) for detection of recombinant peptides or proteins and 2) for purification by selective
dimerization. The first system can be used in assays like western blot: a protein can be produced
by bacteria conjugated with a coil (e.g. E) and detected using labeled K-coil. The K-coil can be
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labeled with biotin, peroxidase, alkaline phosphatase or other labeling systems. In the second
system, the purification is carried out passing the cell-extract through a column containing the
immobilized K-coil peptide. E-coil fusion proteins dimerize with K-coil in the column and are
retained. After washing, the E-protein is eluted; then with chemical or enzymatic processes the
tag can be removed.
The use of E/K fusion proteins is one of most promising techniques, achieving diverse
experimental aims, like studies of mutations in multimeric complexes [146]. Bivalent and
bispecific ScFv-based molecules can be obtained from E. coli encoding two ScFv fragment in as
single peptide (coils have the advantage that disulfide bonds are not required for folding). A
helix-loop-helix motif has been used like dimerization domain for the assembly of dimeric
bispecific miniantibody, replacing the natural immunoglobulin domains [147, 148].
Fusions between coiled coils and other proteins also have been used to study the coiled-coil
motif itself, to understand interactions between α-helices [138, 149-151].
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Chapter 4
The analysis of protein interactions
4.1 The detection of protein-protein interactions: an overview
Proteins interact each other in a high specific manner, and protein interactions play a
important role in many cellular processes, ranging from the formation of cellular structures and
enzymatic complexes to the regulation of signaling pathway. Establishing networks of PPIs will
eventually lead to a better understanding of cellular pathways and functional associations.
Rapid progress in genome projects generated an extensive list of DNA sequences, coding for
proteins with unknown function: only a fraction of gene functions can be inferred from
sequences. Therefore it is necessary to develop strategies to define gene function on a large
scale. The exploration of protein-protein interaction (PPI) on a large-scale or global level is
referred to interactive proteomics, cell-map or interaction proteomics [152].
A first step in defining the function of a gene is to determine the interactions with other
proteins. Most of modern research is concerned with how, where and when proteins interact
with other proteins (and nucleic acids), defining the interactoma. To understand the mechanisms
of protein recognition at the molecular level and to reveal the entire network of protein
interactions in the cell, different experimental techniques have been developed. Some methods
characterize the single protein interaction, while other need for screening of interactions on a
wide-scale genome.
Some of these techniques are:
 Fluorescent resonance energy transfer (FRET) [153]: this is a technique for measuring of
interaction between two proteins. Two different fluorescent molecules (fluorophores) are
genetically fused with two proteins of interest. Upon excitation of the donor, energy is
transferred from the donor to the acceptor in a non-radiative manner via dipole-dipole
coupling.
 Bioluminescence resonance energy transfer (BRET) [154]: one limitation of FRET is the
requirement of external source of light to initiate the energy transfer. BRET uses a
bioluminescent luciferase (typically the luciferase from Renilla reniformis) which catalyze
the oxidation of luciferin to emit light.
 Fluorescent correlation spectroscopy (FCS) [155]: FCS is a typical technique used in
microscopy, to characterize the dynamics of fluorescent species. Light is focused in a
sample and a sensor measures fluctuations in fluorescence intensity caused by the diffusion
or conformational changes of fluorescently labeled molecules in a small volume using
temporal correlation. FCS is used to know average concentrations or kinetic rates.
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 Mass spectroscopy (MS) [156, 157]: it is a powerful method to studying macromolecular
interactions in vitro, identifying the chemical composition of a compound based on a mass-
to-charge ratio of charged particles. The sample undergoes chemical fragmentation forming
ions: they pass through magnetic and electric field and the ratio of charge to mass of the
particles is calculated.
 Surface plasmon resonance (SPR) [158]: SPR is a technique in which biomolecules
capable of binding to specific analytes or ligands are first immobilized on one side of a
metallic film. Light is then focused on the opposite side of the film to excite the surface
plasmons. The refractive index of light reflecting off this surface is measured. When the
immobilized biomolecules are bound by their ligands, an alteration in surface plasmons on
the opposite side of the film is created which is directly proportional to the change in
bound, or absorbed, mass. Binding is measured by changes in the refractive index.
 Two-hybrid system (THS) [159-161]: this method is the most high-throughput interactomic
tool, it has accelerated the screening of protein interactions in vivo. THS has been
developed both in yeast and in bacteria, and it will be exhaustively elucidated in the next
chapter.
4.2 The two-hybrid system
The first THS was developed in yeast by Song and Fields, as an assay to study binary protein
interactions between proteins already know or those strongly suspected to associate [162]. The
system has become the most widely used method to assess both individual PPIs and entire
interactomes.
Yeast two-hybrid system is based on the fact many eukaryotic transcription activators have
at least two distinct domains: a binding domain (BD) that bind the DNA promoter in the DNA
sequence, and an activator domain (AD) that activates transcription. If these domains are
physically separated, they can’t refold in the active protein, producing the gene product after
activation of promoter binding. Song and Fields showed that the transcriptional activity can be
restored if both the domains are expressed with proteins which interact each other
A known protein (bait) is fused to the DNA binding domain and a interacting protein (prey)
is fused to the activation domain of a transcriptional activator. Both fusion proteins are co-
expressed in a appropriate yeast strain that contains sequences for the reporter genes with
transcription depending on the association of two domains. Numerous variations of the THS has
been developed, including using of several reporter genes and three-hybrid systems for the
identification of proteins interactions with DNA or RNA [163].
Only recently the two-hybrid system has been developed in bacteria (BTH). The original
idea of Song and Fields is based on modular structure of transcriptional factors, but only few
bacterial transcriptional factors can be divided on two separated domains. Although this initial
limitation, several systems of BTH have been developed.
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4.3 Bacterial two-hybrid systems
The bacterial two-hybrid system presents some advantages comparing the yeast two-hybrid
system:
- rapid rate growth of cells;
- high transformation efficiency;
- molecular biology methods more suitable for bacteria than yeast;
- nuclear localization of factors is not request;
- eukaryotic domains does not active E. coli genes;
- lower false-positive interactions.
Although with different advantages, BTH is not better than yeast two-hybrid. The two
systems are complementary: each one generate different data which is useful to understand in a
better way the interaction under consideration [164].
Bacterial assays can be divided into 4 categories [165]:
 based on hybrid transcriptional activators [166]: in E. coli, the activation of transcription
of numerous genes involves specific interactions between a protein, which bind a specific
sequence of DNA (operator), and the C-terminus domain of the α-subunit of RNA
polymerase. Dove and his coworkers engineered this system to develop a protein-protein
assay. They constructed two chimeric proteins: the operator-binding protein fused with the
first interactor (X), and the α-subunit of RNA polymerase fused with second interactor (Y).
The chimeric operator-binding protein recognizes the specific activator sequence. When X
and Y interact, the α-subunit of RNA polymerase can recruit other subunits, activating the
reporter gene transcription. As in the case of the yeast, the transcription machinery of
bacteria can be engineered to detect protein-protein interactions.
 hybrid bacterial repressors as reporters of interaction: LexA in E. coli inhibits the
transcription of SOS proteins, which are related to DNA repair and cell division. It
recognize a specific DNA sequence. LexA protein has a modular structure, consisting in a
DNA-binding domain (with no intrinsic basal activity) and in a dimerization domain [167].
Dimerization domain can be replaced by other dimerization motifs or by supposed
interactor proteins, preserving the repressor activity and developing a genetic system to
study protein interactions.
 based on the protein splicing: protein splicing is a in vivo post-traductional process, where
polypeptides are removed from the entire protein. The process is autocatalytic and with
multiple steps: internal fragments of the protein are removed and the flanking sequences
are ligated, generating a functional protein [168]. Enhanced green fluorescence protein
(EGFP) has been used for this method. One interactor (protein A) is expressed fused with
both N-terminus fragments of EGFP and VDE (VMA1-derived endonuclease). An other
interactor (protein B) is expressed fused with C-terminus fragments of EGFP and VDE.
When protein A and B interact, the VDE fragments move closer, they refold in the active
enzyme and the splicing of EGFP starts [169]. The interaction can be measured as
fluorescence emitted by EGFP.
 based on a complementation of enzyme fragments: this method is thoroughly explained in
the next chapter.
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4.3.1 Complementation of enzyme fragments: the protein complementation
assay (PCA)
In protein fragment complementation assay (PCA) strategy, a reporter protein is rationally
dissected into two fragments, and the fragments fused to two proteins that are thought to bind to
each other [170]. The refolding of the reporter protein from its fragments is catalyzed by the
binding of the supposed interactor proteins, and is detected as reconstitution of enzyme activity.
A lot of enzymes can be dissected in two functional domains, but the good candidate should
have some features:
- relatively small and monomeric protein;
- information exists on its structure and function;
- assay must be simple in in vitro and in vivo condition;
- protein over-expression in both eukaryotic and prokaryotic cells;
- the activity of reporter protein must be detectable in vivo.
A fundamental feature of protein fragments is that they cannot fold spontaneously: if this
occurred, PCA simply not works correctly, because it leads to a false-positive signal.
Fig. 1.17 – Representation of PCA strategy. The reporter protein is divided in two inactive domains that are
not able to refold spontaneously. The enzyme activity is restored if the domains are expressed fused to
interactor proteins: the interaction is necessary for detecting re-assembly of catalytically active enzyme from
its fragments.
The design of PCA with the selected reporter starts with the study of three-dimensional
structure of the protein [159]. The critical issue is where to cut: it is important to avoid re-
folding problems, to preserve integrity of the structure and functionality of the refolded reporter.
These problems can be solved studying three-dimensional data about the selected reporter
protein, and also using algorithms which can generate ipotetical fragments analyzing the
residues of the sequence [171, 172].
Another crucial issue is on which terminus to fuse the proteins of interest to the fragments:
in each case, one configuration is favored over any other. Knowing the three-dimensional
structure of the enzyme, it is possible to predict how close both fragments should be to assure
that the domains fold correctly and have a measurable activity. A peptidic linker can be added
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between fragment and interactor to increase the flexibility of entire complex. The linker length
can be adjusted to allow only certain types of orientation of fused protein interaction to occur
[159].
The molecular interaction are detected directly, as reconstitution of enzyme activity, and not
through secondary events such as transcription activation [170]. Moreover, assays based on
enzyme complementation can be performed in any cells types of interest or in diverse cellular
compartments such as the nucleus, cytoplasm or plasma membrane. Different types of PCA in
mammalian cells have been demonstrated [173, 174], and recently also in yeast cells [175].
The bacterial protein complementation assay is a useful method for several aims:
- we can understand how well-know proteins in a biochemical network interact,
observing the role in a specific pathway [170].
- we can also detect new interactors from genomic libraries, or characterize a protein with
unknown function [176].
- for pharmacological aims, it is possible to screen molecules that promote or disrupt
some important interactions, which could be applied to drug discovery [174].
- the system is also useful for high-throughput screening of libraries [138, 149, 177, 178],
but the interactors must be confirmed with others different techniques, avoiding
problems of false-positive and false-negative results [179].
- additionally, PCA has been used to isolate antibody-antigen interaction and to select
antibodies from a library [177, 178, 180, 181].
Several proteins can be used as a reporter for PCA. The following proteins have been used
with good results:
 mouse dihydrofolate reductase (mDHFR): functional mDHFR confers on bacteria the
ability to grow in presence of antibiotic: it can be dissected in two domains, fragment I
and fragment II. The two divided fragments can not fold in the active protein. The
folding happens only if they are expressed in framework with two interacting partners,
allowing to the two halves of mDHFR to come into close contact, thus restoring its
enzymatic activity. The E. coli DHFR is inhibited by the antibiotic trimethoprim,
whereas the mDHFR does not show inhibition [177, 178].
 adenylate cyclase: the adenylate cyclase calmodulin-dependent (CyaA) is an essential
toxin for the virulence of B. pertussis. When the bacteria infect eukaryotic cells, the
enzyme is stimulated by endogenous calmodulin, activating the production of cAMP at
non-physiological levels [182]. CyaA can be dissected proteolitically in two domains,
generating the fragments T25 and T18. Two supposed interactors are expressed like
fusion proteins in framework with fragments: the association of the hybrid proteins
permit functional complementation of the active enzyme. This method are based on
reconstitution of a signal pathway with the involvement of cAMP, in a cya- E. coil strain
[176].
 green fluorescent protein (GFP): isolated from jellyfish A. Victoria, GFP fluoresces
green when exposed to blue light. It was shown that the protein can be splitted on two
fragments: fluorescence of active GFP are achieved when the fragments reassemble, and
only if they are fused with interacting peptides. This method was used to test the
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strongly association of anti-parallel leucine zippers [183] and to isolate novel substrates
for kinases [184].
 β-lactamase: the BTH system based on this enzyme is thoroughly explained in the
following chapter.
4.3.2 The β-lactamase-based protein complement assay
Β-lactamase is an hydrolase secreted in the periplasmic space by gram negative bacteria. It is
a protein responsible for the resistance of the β-lactam antibiotics like penicillin, cephalosporins
and cephamycins. The β-lactamase cuts β-lactam ring, deactivating it. The β-lactam antibiotics
interfere in a specific way with the biosynthesis of peptidoglycan, the major constituent of
bacterial cell wall, essential also for the shape and rigidity of the cell [185].
Fig. 1.18 – Three-dimensional model of TEM-1 β-lactamase.
β-lactamase is expressed in several isoforms: TEM-1, from E. coli, is the most commonly-
encountered enzyme. It is a particular attractive candidate for an assay based on enzyme
fragment complementation because it is monomeric, with relatively small size (29 kDa protein),
well characterized concerning structure and function. In addition, β-lactamase is expressed
successfully in prokaryotic and eukaryotic cells, making this system applicable in both classes
of cells, and no orthologs exist in mammalian cells [186, 187]. It is a good reporter protein for
PCA because permit the generation of signal as a direct result of interaction: the functional
enzyme confers on bacteria the ability to grow in presence of antibiotic. Additionally, it has
been used to set up a model systems for fluorescence-based monitoring of β-lactamase activity
in living bacterial or eukaryotic cell [188].
The PCA strategy requires the design of optimal dissected fragments, to permit their
assembling and folding after that proteins of interest have interact. The TEM-1 β-lactamase can
be splitted, generating two polypeptides of 10 kDa and 19 kDa, namely the α-peptide and ω-
peptide respectively, that are unable to refold spontaneously. The site used to split the enzyme
in these two polypeptides (G195/L196) is not located close to the catalytic site. A point
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mutations on the residue 182 (substitution of Met with a Thr) allows a better folding and
increase the stability of the reconstituted enzyme [189].
Like other PCAs, the protein complementation assay based on TEM-1 β-lactamase needs of
two different vectors for the expression of reporter fragments. The pα vector contains the α-
peptide, corresponding to residues 1-195, whereas the pω vector contains the ω-peptide,
corresponding to residues 196-286. An interactor protein can be cloned with the correct
framework in each vector. Only bacteria cells that express interactor proteins can complement
β-lactamase fragments and survive in ampicillin plates.
Fig. 1.19 – β-lactamase-based PCA strategy. Two potentially interacting protein are expressed in fusion with
the α and ω fragments of the β-lactamase: the fragments complementation upon interaction leads to restored
enzyme activity. The ampicillin is hydrolised by the lactamase and bacterial growth is observed (right). If the
in fusion peptides are non-interactor proteins, the lactamase is not complemented and the bacterial growth is
impeded by the intact antibiotic (left). The presence of colonies onto the plates is the direct signal of the
complementation.
A periplasmic secretory signal of 23 residues is included at the N-terminus of each
recombinant protein: so, the fusion polypeptides can translocate and interact into the
periplasmic space of the cells [181]. If recombinant proteins lack the periplasmic signal, the
complementation takes place only at the cytoplasmic level
The beta-lactamase PCA can be useful for several aims:
- to construct interaction maps of several proteomes;
- to identify interactions between proteins of two different proteomes;
- to understand the role of a protein in a specific biochemical network;
- to identify molecules that inhibit interaction between well-known proteins, like peptides
in signal transduction pathways [190];
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- as consequence of previous point, to test molecules (drugs) that can interfere with
protein interaction: this can be useful to understand;
- to select antibodies against specific protein and to complete an epitope mapping of
interaction [181];
4.3.3 Selection of scaffold libraries by use of PCA
The protein complementation assay is a powerful method for measuring protein-protein
interactions in biological systems. It can be exploited to understand the role of a protein in a
specific biochemical network or to verify how some molecules (e.g. drugs) can interfere in
protein interaction. Protein interaction are involved in all biochemical pathways, and the PCA
ca be useful to characterized a protein with unknown function [170].
The system was used to demonstrate that single-chain antibodies libraries can be screened to
antibodies that recognize specific antigens [177]. In this assay, the antibody library and the
antigen were expressed genetically fused to the fragments of mDHFR enzyme. If an antibody
bind the antigen, the binding event ca be detected or selected for by the reconstitution of
enzyme activity. By using and optimizing the length of a linker between the protein and the
fragment, the interaction of proteins with steric hindrance can be improved.
The PCA was already used for the selection of new scaffold proteins: Amstutz and
colleagues described a method to select specific MAP-kinase binders from a library of DARPins
[191]. The application was improved when a pre-selection step was introduced using ribosome
display. In other works, the stability and affinity of some protein scaffolds were improved:
scaffold libraries of coiled-coil proteins were generated by mutating or randomizing specific
residue into the sequence, and using the PCA as selection method to isolate improved-coils
peptides [106, 138, 149-151, 179, 180].
The interaction of activator protein-1 (AP-1) factors c-Fos and c-Jun was deeply analyzed.
AP-1 is a transcription factor involved in numerous types of cancer: the leucine-zipper region of
c-Jun and c-Fos components allow the dimerization and the complex activity. Using these
leucine-zipper regions as a template, the sequences were modified, generating libraries and
testing them to find improved binders [106, 138, 149, 150]. The interesting idea is the concept
of modifications: in this approach, the libraries were constructed by mutating rationally the
residues in specific positions, (the apolar core and the charged external regions), optimizing the
core packing, α-helical propensity and electrostatics. With the PCA, new interactors with
biomedical potential were isolated and characterized (wJun and wFos) [192]. Hagemann and
coworkers compared the ability of these peptides to disrupt the cFos/cJun interaction to new
binders selected with a different selection technique, the phage display [179].
In a recent work, a similar approach was performed to disrupt the interaction between Myc
and Max proteins, due to the presence of a coiled-coil dimerization domain [151]. Myc is
involved in several pathways, as cell proliferation and apoptosis; it is frequently deregulated in
human cancers, but for the carcinogenic function the dimerization with Max is crucial. Jouaux
and coworkers applied a rational mutagenesis to the Max sequence, to generate a library of
binder variants. They randomized residues important for interaction, and the selection was
carried out using PCA. Two peptides were isolated because they disrupt the Myc-Max dimer
formation: consequently, inactivation of Myc provides a new therapeutic opportunity.
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4.4 The display systems
More than 20 years have passed since the first display techniques were developed and the
relevance of this method allowed to expand the principle to different systems [193]. The
principle underlying display technologies is the physical association between phenotype of
polypeptides under analysis and the genotype. This means that the identification of displayed
protein lead to the isolation of sequence encoding for that protein. The sequence can be
immediately characterized and modified with molecular biology tools and genetic engineering
methods.
From the first display method, one concept is strengthened: it is possible to create a
collection of billions of different displayed particles displaying different polypeptides, named
“display libraries”. From these huge collections we can isolate the protein of interest: since the
methodology provides a link between the phenotype and the genotype, the isolate particle keep
also the genetic information.
The display technologies can be divided in 5 major categories, according to the platform
used for the specific method [194]:
- Ribosome display: this method was the first cell-free in vitro display assay developed
[195]. The link between phenotype and genotype is accomplished during in vitro
translation by stabilizing the complex consisting of the ribosome, the mRNA and the
nascent, correctly folded polypeptide. The entire complex is used for selection steps.
Avoiding the transformation step, the diversity of the library is not limited by the
transformation efficiency of bacterial cells, but only by the number of ribosomes and
different mRNA molecules;
- DNA display: it is a selection strategy in which individual proteins are covalently linked
to the cognate encoding DNA template in separate droplets of a water-in-oil emulsion
[196]. It exploits the unusual property of endonuclease P2A of E. coli bacteriophage P2:
the endonuclease P2A initiates the DNA replication of the bacteriophage P2 by making a
covalent bond with its own phosphate backbone. This enzyme has been exploited as a
new in vitro display tool for antibody fragments, constructing hybrid protein with P2A
protein.
- mRNA display [197]: the translated peptides are covalently linked with their coding
mRNA with the puromycin, a peptidyl acceptor antibiotic Ribosome moves along the
mRNA template: when ribosome reaches the end of template, the puromycin enters in
the ribosome and is incorporated into the polypeptide. Some unique applications are
possible with mRNA display, including library construction with unnatural amino acids
[198]. Like the ribosome display, the major advantage of this method is that it is entirely
performed in vitro, avoiding the transformation step in cells;
- Cell display: in this display method, the chimeric protein is expressed and exposed by
surface of bacteria, yeast or mammalian cells. Systems based on bacteria cells has been
tested to display functional enzymes, vaccine antigens and polypeptide libraries, also
with tolerated insertions of more than 100 residues [199]. A large number of membrane
proteins is useful for this approach, like OmpA, OmpC, LamB and BtuB, extensively
modified and improved for more efficient system. Yeast display provides an advantage
over bacteria system, for secreted proteins that require post-translational modifications
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for correct folding and activity. For biomedical application, the use of mammalian cells
has been improved, avoiding bacteria and yeast limitations like the different codon usage
and some restriction on post-translational modification [200].
- Phage display: phage display is the most well-studied high-throughput screening
method to study protein interactions, based on displaying peptides or proteins on the
surface of a bacteriophage. The system will be thoroughly explained in the next section.
4.4.1 The phage display technology
The origin of the phage display dates to the mid-80s when Smith first expressed a foreign
segment of protein on the surface of bacteriophage M13 virus particle [193]. Smith
demonstrated that a fusion phage can be isolate from a background of phage particles displaying
no antigen with more than 1000-fold enrichment, allowing phages displaying the correct antigen
to be affinity purified against the cognate antibody.
Fig. 1.20 – M13 bacteriophage structure: proteins which compose the capsid are indicated.
Filamentous bacteriophages are a group of related virus that infect only gram-negative
bacteria. The most investigated are fF phages, including fd, f1 and M13 [201]. The genetic
material consist on a single-stranded circular DNA molecule (6407 nucleotide long),
encapsulated in a protein capsid. The genome of fF phages encodes 11 genes grouped according
to their function: DNA replication, capsid packing and encoding proteins involved in phage
membrane assembly [202]. The DNA is encased in a capsid composed by approximately 2700
copies of the major coat protein P8, and capped with 5 copies of four different minor proteins
(P9, P7, P6, P3). The minor coat protein P3 binds to the receptor at the tip of the F-pilus of the
host E. coli. For phage display system, the most important proteins are P3 and P8.
Thanks to their structure, their replication and packing processes (not limited by DNA size),
these phages are useful tools to express recombinant proteins. With molecular methods, the
DNA sequences of interest can be embedded in the phage genome with the correct framework
of the genes coding for P3 or P8. The exogenous peptide are displayed on the phage surface in
fusion with capsid proteins [203].
The principles of phage display are that the coat proteins of fF phages might tolerate being
fused to foreign polypeptides without losing their function, and that the fused foreign
polypeptide can be displayed on the surface of the filamentous phage. The general concept is
that a phage encoding a specific fusion protein on its surface, could be isolated for its binding
property to a given protein from a collection of billions of phages with different exposed
proteins. As for other display systems, phage display provides a physical link between the
phenotype and the genotype; the fact that the gene encoding a protein, selected for a specific
property, is found within the phage displaying the protein itself, means that cloning of the gene
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occurs simultaneously with the selection of the phage. The ease and rapidity of DNA sequence
analysis permit to identify quickly the selected molecules.
Generally, the phage display cycle starts with the creation of diversity at the DNA level,
creating a library of different variants. The DNA fragments are usually cloned upstream the
gene encoding the protein 3 or the protein 8 of the phage: in the first case, there are 3 to 5
recombinant proteins at one end of the phage; in the second, all 2700 copies of the major coat
protein are recombinant. Excluding the display of short peptides, the protein 3 based system is
generally preferred. Although, P3 and P8 have been used to display proteins, P3 is the display
protein par excellence, having been used to display large numbers of different proteins.
Fig. 1.21 – Schematic representation of a typical round selection: the elute, enriched in phages that bind the
target molecule, is used for the next selection round. After 3-5 rounds, the library is enriched in phages that
clearly bind the target material.
A typical selection round is illustrated in figure 1.21. In the phage display cycle, the phage
displaying the protein of interest P is retained on a surface, coated with an antigen or an
antibody recognizing P, while non-adherent phages are washed away. Bound phages can be
removed from the surface, re-infected into bacteria and re-grow for further enrichment and
eventually for binding analysis. The possibility to perform successive round of selection permits
the isolation of proteins present in very low number in a population of billions of different
phages. Usually, three or five rounds of panning are sufficient to enrich for binding peptide
sequence.
Phagemid vectors have been developed as it is extremely difficult to work with phage
genomes. These vectors, containing an Ff origin of replication and the gene encoding protein 3,
can be manipulated and propagated as plasmids, and when display is required bacteria
containing the vectors are infected with a helper phage, which provides all other components
necessary for the creation of recombinant, selectable, phage particles.
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4.5 Applications of polypeptide libraries
One of the most impressive aspects of the phage display is the variety of uses of this
technology. Smith and his group have first used libraries displaying short peptides on antibodies
for mapping antibody epitopes with that technique [193]. The increasing availability of
structural data and genomic sequences of proteins provides new opportunity for the construction
of improved phage libraries [204, 205].
The phage display technique allows the construction of protein libraries for several aims, like
to find “consensus” sequences responsible of the protein-protein interaction, for epitope
mapping or to find ligands of specific receptors, and for different final applications like protein
microarrays [91], drug targeting and delivery and environmental monitoring [206].
A huge number of applications has been proposed for phage display techniques:
Combinatorial peptide libraries: random linear and cyclic peptide libraries and antigen- or gene
fragment libraries have been used for the epitope mapping of monoclonal
antibodies. Combinatorial peptide libraries, which can be constructed to contain
billions of unique peptide sequences, have been a powerful source of molecules
with different binding potential [207]. These libraries have served to identify
protein binding sites, new substrates for enzymes, or peptide ligands for proteins
involved in interactions. Peptide libraries have also been selected for motifs
mimicking epitopes of antibodies produced in diseases [208].
Immunological peptide libraries: molecules naturally involved in immune recognition have
been heavily exploited in display technologies. The two basic types of
immunological interactions include (1) binding of antibody to an antigen and (2)
binding of a T cell receptor (TCR) to a major histocompatibility complex (MHC)-
presented antigen-derived peptide. The structural diversity between antibodies and
TCRs has turned them into suitable platforms for construction of display libraries
and as sources of specific and functional antigen-targeting molecules.
The most important and widely used application for immunological libraries is
represented by antibody phage display [209, 210]. The entire antibody repertoire of
the immune system could be transferred into this in vitro system, and used to select
antibodies with a given specificity. Several monoclonal antibodies have been
isolated and approved by the US Food and Drug Administration (FDA), and have
been used as therapeutics in the clinic for several years [211]. Screening of
antibody libraries aimed at the isolation of prototype drugs targeting cancer,
infections and other diseases is one of the main approaches to target discovery and
validation [212].
cDNA libraries: Display methods in general are limited in terms of the length of polypeptide
translated from the library clones. For phage display system, longer polypeptides
have a higher chance of disrupting virion functions, such as assembly and
infectivity. In addition full-length cDNAs generally contain several stop codons
near their 3’ end.
These problems impeded the progress of display systems based on full-length
cDNAs libraries. Initial breakthroughs were achieved with libraries displaying
protein fragments. Such proteins domain libraries have been developed for
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antibody epitope mapping to directly and unequivocally identify the antigen.
Procedures for display cloning of cDNAs have evolved significantly since then,
and monovalent phage display relying on helper phage has made whole protein
presentation possible [213].
Scaffold libraries: antibodies are predominantly used to display permutated polypeptide
sequence into a preserved protein domains. There are many other novel library
frameworks that may be adopted for the presentation of polypeptides in display
libraries [207]. The exposed loops that link structural elements of the protein (α-
helices and β-sheets) are accessible for ligand binding and can accommodate
sequence variation without changing overall structure and stability of the
underlying scaffold.
In the last years many non-conventional scaffolds have been developed and used in
protein display systems, like a good alternative to antibodies. Small dimensions,
tolerance to multiple substitution and great stability are some features of these new
tools.
Aim of the research
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Aim of the research
The advancements in biotechnology research allow the development of new biosensors,
improved by nanotechnology knowledge: the use of new materials, or the exploiting of new
physical-chemical proprieties emphasizing at nano-scale, allows the production of micro- and
nano-devices with high biosensing potential.
Generally, a biological component is needed in bioanalytical device: several biological
molecules have been considered and used for different purposes, such as antibodies, enzymes
or oligonucleotides (DNA). Recently, a new generation of protein scaffolds has been developed:
these structures, like antibodies, can recognize and bind specific molecules with high affinity,
but possess smaller size, an important feature for a potential nanotechnological application.
The peculiar dimerization tendency of some proteins can be employed to build up specific
biosensors. For example, the coiled-coil domain -a widely spread dimerization domain- is
involved in protein-protein interaction in both eukaryotic and prokaryotic cells. The analysis of
the sequence and 3D structure of these domains allows an ex novo design of new peptides,
named E and K, which can interact with each other with high affinity and specificity. A deep
characterization of their physical-chemical features has been performed. The stability of this
interaction makes the coiled-coil domain an ideal platform to produce a fully functional and
customized biosensor.
The aim of the present work is the study of the E/K structure, in order to understand if the
dimerization of this coiled-coil domain can be used for biosensing applications, further
improved with biological techniques.
Therefore, the main objectives of this research are:
1) the characterization of the E/K interaction in an in vivo systems;
2) to verify if E and K peptides of the coiled-coil domain possess a backbone that can
tolerate sequence modifications, so that they can be considered scaffold proteins;
3) the design of strategical modification, allowing the isolation of new coils, with improved
stability and affinity respect to E and K wild type coils;
4) the validation of dimerization capability of these new peptides with adequate in vitro
tests, in order to verify the quality of interaction improvements;
5) the development of new scaffold protein, that can recognize and bind small molecules.
Such new structure can be used as a biosensor units for nanotechnological platforms, e.g.
micro- and nano-array.
The outcome of this research could allow the future development of arrays with co-
transcriptional/translational techniques.
Results
49
Results
Chapter 1
The E/K coiled-coil domain: in vivo validation
1.1 The protein complementation assay to validate E/K dimer
The E and K coils are a result of de novo peptide design, based on the knowledge that natural
proteins can dimerize using α-helical domains. The physical and chemical proprieties
characterizing this kind of interaction have been deeply characterized using circular dichroism,
a technique that allows to resolve the structure of biological macromolecules, in particular the
secondary structure of proteins. .
In order to validate the data obtained with physical methods, an in vivo assay is necessary to
corroborate the dimerization capability and effective functionality of the coiled-coil domain. To
this purpose, the protein complementation assay was used to validate the interaction between
these peptides.
With the aim to develop a strategy for in vivo protein-protein interaction analysis and for
high throughput screening of libraries, we employed a PCA based on the ampicillin resistance
protein TEM-1 β-lactamase. The method has been extensively described in the introduction
(paragraph 4.4.2). Briefly, a reporter protein is rationally divided in two fragments, unable to
refold spontaneously, that are in turn fused to two proteins supposed to bind to each other. The
refolding of the reporter protein, detected as reconstitution of its enzymatic activity, takes place
only if the two proteins effectively interact.
1.2 Setup of PCA: pα and pω expression vectors
The first step of this work was to setup suitable expression vectors to perform a TEM-1 β-
lactamase-based PCA. Like other PCAs, the protein complementation assay based on this
enzyme needs two different vectors for the expression of reporter fragments: the pα vector
contains the α domain, whereas the pω vector contains the second subunit, the ω domain. Both 
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plasmids are derived from the pBluescript [214] vector, whose beta-lactamase gene has been
substituted by the kanamycin (kan) or chloramphenicol (Chl) resistance genes in pα and pω 
respectively. The β-lactamase coding sequence of pUC119 plasmid was used as template to
generate fragments by PCR [181].
The pAlfa (pα) vector is constituted by the following cassettes:
- the kanamycin resistance cassette;
- the inducible lacZ promoter (Plac), to allow the control of the expression of the
recombinant protein;
- the leader sequence proper of TEM-1 β-lactamase protein, to guide the proper secretion
into the periplasmic space;
- the α domain, encompassing residues 1-195 of the β-lactamase ORF;
- a tripeptide sequence NGR, able to improve β-lactamase complementation;
- a glycine-serine (GS) linker;
- the wild type sequence of E-coil, with flanking 5’ EcoRI and 3’ HindIII restriction sites;
- an hstidine tag (HIS), to detect the recombinant protein..
Fig. 2.1 – Schematic representation of pα vector. The expression of the recombinant protein is under the
control of a Lac promoter, and can be monitored by using the His tag; the translocation into the periplasmic
space is under the control of the lactamase leader sequence. The Ewt sequence is subcloned in fusion with the
α-fragment of lactamase, the glycine-serine linker and the NGR sequence, able to improve enzyme
complementation.
pOmega (pω)  vector is constituted by the following cassettes:
- the chloramphenicol resistance cassette;
- the inducible lacZ promoter (Plac), to allow the control of the expression of the
recombinant protein;
- a leader sequence to guide the correct secretion into the periplasmic space;
- the wild type sequence of K-coil with flanking 5’ BssHII and 3’ NheI restriction sites;
- an SV5 tag, to detect the recombinant protein;
- the ω domain, encompassing residues 196-286 of the β-lactamase ORF.
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Fig. 2.2 - Schematic representation of the pω vector. The Kwt sequence is subcloned in fusion with the ω-
fragment of lactamase The expression of the recombinant protein is under the control of a Lac promoter, and
the production can be detected by using the SV5 tag; the translocation into the periplasmic space is under the
control of the bacterial PelB leader.
The 3D folding of these chimeras is shown in figure 2.3.
Fig. 2.3 – Three-dimensional molecular models of α-Ewt and ω-Kwt: the coils are labeled in red, the α
fragment is labeled in yellow, the ω fragment in green.
In this thesis, the coils described by Tripet and Chao are named “wild type E” (Ewt) and
“wild type K” (Kwt).
1.3 Cloning and validation of wild type E and K-coils
The E and K sequences were amplified through polymerase chain reaction (PCR). The first
step was the design of primers, whose sequence has been derived from the amino acid sequence.
The strategy to obtain the full fragments was based on the self-annealing of complementary 3’
ends and extension of primers.
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Fig. 2.4 – Scheme of the adopted strategy to obtain the full sequence of K wild type coil. The same strategy
was applied to the Ewt coil.
Because each of the five heptads constituting E or K coils has the very same amino acid
sequence, in order to guarantee the correct primer annealing in following PCR amplifications
and avoid undesired base pairing that would lead to aberrant PCR products, it was necessary to
design appropriate primers. Exploiting the redundancy of the genetic code, the same residue in
different heptads was encoded by different codons, so that the nucleotide sequence was as more
variable as possible, avoiding internal self annealing and allowing correct base-pairing during
subsequent rounds of PCR ends.
Table 2.5 – The nucleotide sequence of Ewt and Kwt, derived from the amino acid sequence: in each coil, the
residues in the same position were encoded by different codons in different heptads. The nucleotide sequence
was the basis for the primer design.
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On the basis of these sequences, a pair of forward and reverse primers for each coil was
designed, with a 3’terminal sequence homology to allow self-assembly and 5’ terminal
restriction sites (BssHII/NheI for Kwt, EcoRI/HindIII for Ewt). PCR products were
subsequently purified, digested and ligated with compatible digested vectors, generating pα-Ewt
and pω-Kwt plasmids in transformed E. coli DH5α competent cells.
Positive colonies were sequenced to verify the correctness of the peptide sequences. The
expression of α-Ewt and ω-Kwt fusion proteins and their effective export into the periplasmic
space was induced treating bacteria with IPTG, that activates Lac promoter and downstream
cassettes, and loading samples on SDS-PAGE to detect recombinant proteins with anti-tag
antibodies.
Fig. 2.6 – Western blot assay to check the size and the expression level of fusion proteins α-Ewt and ω-Kwt.
The SDS-PAGE was loaded with total (TOT) and periplasmic (PP) fractions of DH5α induced for the
expression of both Ewt in fusion with the α fragment and the Kwt in fusion with ω fragment of the β-
lactamase. The arrows indicate the predicted molecular weights of the fusion proteins. Primary antibody:
mouse anti-His 1:5000 (α-Ewt), mouse anti-SV5 1:2000 (ω-Kwt). Secondary antibody: goat anti-mouse AP
conjugated 1:2000.
The immunoblot shows that the proteins were correctly processed: the arrows indicate the
predicted molecular weight, corresponding to about 30 kDa for α-Ewt and 19kDa for ω-Kwt.
1.4 The PCA of wild type E/K coiled-coil domain
The PCA was performed to determine if the coils are able to interact in a in vivo system. The
goal was to verify the reconstitution of β-lactamase activity and, consequently, the bacterial
growth on plates supplemented with ampicillin. As control plasmids, in order to test the
interaction specificity between E and K coils, a scFv (ΔG2) specific for the V. cholerae toxin
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ΔG was cloned into the pω expression vector, and the tissue transglutaminase (tTG), an enzyme
that catalyzes the cross-link between glutamine residues and polyamines, was cloned in pα.
E. coli DH5α cells were co-transformed with the following pα and pω constructs:
- pα-Ewt / pω-Kwt;
- pα-Ewt / pω-ΔG2;
- pα-tTG / pω-Kwt.
Bacteria transformed with only one vector did not grow in presence of ampicillin, ruling out
any possible intrinsic antibiotic resistance (data not show). DH5α cells were also transformed
with pUC119 (Invitrogen) to verify the bacterial growth of cells with an ampicillin resistance
given by an intact and non-fragmented β-lactamase. All the co-transformed bacteria were plated
onto agar plates containing either chloramphenicol/kanamycin, to confirm the presence of both
vectors, or increasing amounts of ampicillin to assess the sensibility of the complementation
system.
As yet explained in the paragraph 1.2, the pα vector contains the gene for kanamycin
resistance, pω the gene for chloramphenicol resistance. In the chloramphenicol/kanamycin plate
the growth is allowed only for the bacteria that contain both vectors, pα and pω. Therefore, with 
this plate it is not possible to know something about interaction among the peptides. That
information can be obtained from ampicillin plates, because this antibiotic selects bacteria
producing two interactor peptides. Only interactors can reconstitute the β-lactamase: the active
enzyme can break the β-lactam ring of antibiotic, and the growth of bacteria is permitted.
Fig. 2.7 – Percentage of bacterial survival of DH5α transformed with pUC119, and co-transformed with pα-
Ewt and pω-Kwt, pα-tTG and pω-Kwt, pα-Ewt and pω-ΔG2: the number of colonies growing on 
chloramphenicol/kanamycin plates, indicating the number of co-transformants, were set to 100%. The
number of colonies grown on different ampicillin concentrations were compared with 100%.
The formation of ampicillin resistant colonies was observed only in bacteria co-transformed
with pα-Ewt and pω-Kwt, and transformed with pUC119. From graph in fig 2.7, one can
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appreciate how the number of colonies was inversely correlated to the concentration of
ampicillin, indicating PCA is a system sensible to antibiotic toxicity; whereas, bacteria with an
intact β-lactamase grown without a detectable decrease. The graph confirms that wild type E
and K coils strongly interact in vivo: the binding of the two coils reassembles the lactamase and
reconstitutes its activity, corroborating the interaction data obtained with circular dichroism. A
3D-interaction model of the wild type coiled-coil domain with complemented α and ω domains 
is reported in fig 2.8.
Fig. 2.8 – Three-dimensional molecular model of the interaction between α-Ewt and ω-Kwt the fusion
proteins (α fragment in yellow, ω fragments in green).
Moreover, it was demonstrated that the activity of the complemented lactamase is more
sensible to antibiotic than the non-fragmented enzyme. No colonies were detected onto the
plates with the other combinations of co-transformed bacteria, even at low ampicillin
concentrations; these observations confirm that the complementation of β-lactamase and its
activity are strictly dependent on E and K interaction.
.
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Chapter 2
The wild type E/K domain as a scaffold
2.1 Engineering of a coiled-coil domain
As described in details in chapter 2, scaffolds are binding reagents which may be employed
in a wide range of biotechnological and biomedical applications. Modified scaffolds can be
selected with both in vitro and in vivo techniques, allowing the isolation of new molecules with
improved affinity against specific ligands [84].
The second aim of this project was to understand if wild type E and K peptides can be
considered scaffold proteins. Generally, to use a protein as a scaffold some basic requirements
should be considered:
 high stability;
 high interaction affinity;
 small size;
 easy expression in bacteria and eukaryotic cells;
 the folded protein (and the overall stability of the whole molecule) must be tolerant to
sequence modification;
The last point is a fundamental feature of scaffolds: the native protein folding must not be
altered by the modification or insertion of additional residues, reflecting the elasticity of
supporting structures (or frameworks) which can exhibit a novel binding capability. Moreover,
these structures may be obtained by rational, or most commonly, combinatorial protein
engineering techniques prone to further improvements and modifications [85].
In this section all these requirements have been taken in consideration, according to previous
reports [114, 135-137, 144, 145]. Moreover, we previously obtained good results about the
ease of coil expression in bacteria, even if fused to β-lactamase fragments.
In order to assess the tolerance to modifications of the sequence, some mutations were
inserted in the wild type E and K sequence. The resulting interactions were analyzed and
validated.
2.2 Construction of E and K mutant coils
Considering the structure of E and K coils, the mutations were inserted only into the central
heptad of the peptides. To this purpose, glycine was considered because of the small size and
the absence of charge.
Two different strategies were applied to verify potential alterations of stability:
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1. mutations of the most important residues for the E/K interaction: a and d into the apolar
core, e and g into the external charged region. The new coils were named Emut and
Kmut;
2. mutation of the whole central heptad with glycine residues only. The new coils were
named Egly and Kgly.
Fig. 2.9 – A scheme of the two strategies applied to verify the alteration of stability of E and K coils. In the
first strategy, the substitution of apolar core and charged region residues with glycines, while in the second
strategy the substitution of whole central heptad residues.
All mutant coils were created by PCR amplification: the sequences of Ewt and Kwt were
used as templates, and three subsequent rounds of PCR were performed to introduce desired
mutations. Concerning the two strategies, correct primers were designed to introduce codons
that translate for glycines into the considered positions. In the following figure, the PCR
strategy for Egly coil is depicted.
Fig. 2.10 – Schematic representation of the three subsequent rounds of PCR necessary for the construction of
the glycine-mutant coils. The same strategy was also applied to generate all mutants coils.
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With the first cycle of PCR, the mutagenized region inserted into the forward primer was
already introduced into the peptide. With the second and third amplification rounds, the entire
peptide was generated. The PCR products with proper 5’ and 3’ restriction sites were cloned
into the correct vector. Emut and Egly were cloned into pα vector, Kmut and Kgly into pω 
vector, respectively.
The detailed cloning procedure is reported in the material and methods section.
2.3 Validation of E and K mutant coils
The first validation of new peptides was given by sequencing, to verify the correct cloned
sequence of the central heptad.
The next step was to assess if the mutate coils can effectively interact as a stable
heterodimer: to this purpose the protein complementation assay was performed. The aim was to
compare the bacterial growth on plates with increasing concentration of ampicillin. E. coli
DH5α cells were co-transformed with each pα and pω construct. As explained, the heterodimers 
tested for interactions were:
- pα-Ewt / pω-Kwt, as positive control;
- pα-Emut / pω-Kmut;
- pα-Egly / pω-Kwt;
- pα-Ewt / pω-Kgly.
Fig. 2.11 – Helical wheel representation of the three new heterodimers, tested in PCA. The glycine-
mutagenized residues are labeled in red.
Bacteria were plated onto agar plates containing either chloramphenicol/kanamycin or
increasing amounts of ampicillin (from 50 μg/ml to 1200 μg/ml) and 1mM IPTG; the plates
were incubated for 48 hours at 28°C. The survival ratio of each clone was calculated, comparing
the growth rate on chloramphenicol/kanamycin and on ampicillin plates. The antibiotic
sensitivity could be a simple means to select clones which express stable recombinant proteins
among genetically homogenous cells.
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Bacteria were grown on chloramphenicol/kanamycin plates to confirm the effective co-
transformation, without giving any useful information about the E/K interaction. The latter was
obtained plating cells on increasing ampicillin concentrations, in order to select functional
interactions between coils. As show in figure 2.12, the formation of ampicillin-resistant colonies
was observed in all co-transformed cells, but with different trends for each new heterodimer.
Fig. 2.12 – Bacterial growth of DH5α co-transformed with pα-Ewt and pω-Kwt, pα-Egly and pω-Kwt, pα-
Ewt and pω-Kgly, pα-Emut and pω-Kmut. The number of colonies growing on chloramphenicol/kanamycin
plates, indicating the number of co-transformed bacteria, were set to 100%. The number of colonies grew on
different ampicillin concentrations were compared with 100%.
The results clearly show that some modification compromised the stability of coils
interaction. The Emut/Kmut dimer possess the best stability and affinity, reflecting increased
antibiotic resistance, even if both coils were modified; interestingly, the mono-mutated dimer
Ewt/Kgly is significantly more stable than Egly/Kwt. Therefore, even if with different activities,
both mutated E and K peptides can fold to form an α-helix domain and interact with each other.
According to Tripet and Chao [114, 136], each coil alone should present a random structure,
that spontaneously folds into ordered α-helical motif to form a right-handed supercoil in
presence of the complementary coil. We demonstrated that the wild type K-coil is more tolerant
to sequence modification than the E-coil to allow this folding.
Therefore we can conclude that wild type E and K coils can be classified as scaffold proteins
because they retain basic requirements even in presence of sequence alterations. Concerning the
modifications, it seems that the K-coil is more resistant and stable than the E-coil, at least for
the central heptad repeat mutation. Given these results, we focused our attention on the K-coil,
in order to improve in vivo and in vitro performances of this heterodimeric coiled-coil complex
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Chapter 3
Improving the wild type E/K dimer:
the K random coils.
3.1 Introduction
Chao and coworkers designed a de novo heterodimeric coiled-coil domain after having
analyzed the structure of natural coiled-coils [135, 136]. This wt E/K system was employed in
purification systems and for biosensing applications, in virtue of the extremely stable and
specific dimerization of E and K peptides. However, some experimental procedures often
require extreme pH, redox and ionic strength conditions that could interfere or even disrupt the
interactions between the coils and therefore alter the results of the assay. For this reason the
development of improved coils with increased stability and specificity is needed.
Likely to previous studies, the interaction quality of protein scaffolds was ameliorated
mutating specific residues into the sequence and selecting new peptides with improved features
with [106, 138, 149-151, 179, 180]. In the previous section it was demonstrated that the K-coils
is more tolerant to sequence modification than the E-coil. Then, the wild type sequence of K-
coil was modified, and a set of new heterodimerization domains was obtained with different
interaction abilities, that were selected through β-lactamase-based PCA.
Two different strategies were tested to improve the previously selected heterodimeric coiled-
coil domain, optimizing the core packaging, α-helical structure propensity and electrostatic
features :
1) in the first approach, the whole central heptad was randomly mutagenized (a-b-c-d-e-f-g),
substituting each residue with one of 20 natural available amino acids. Any type of
arrangement can be obtained, and a collection of different peptides was created: the
Krandom library (Kran);
2) in the second approach, the mutagenesis was applied on the whole sequence of the peptide,
not only in the central heptad. Here, only the residues fundamental for the interaction and
dimerization were mutated, i.e. the amino acids in the apolar core (a and d) and in the
charged external region (e and g). Secondly, the mutated positions were substituted not with
any of the 20 natural amino acids, but only with ones sharing common charge and polarity
(apolar residues for the hydrophobic core and charged or polar residues at the external
surface).
Since the library was constructed with a rational design based on K-coil sequence, it was
identified as a library of K rational design peptides (Krd).
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3.2 Construction of the pω-K random library
As already explained in the previous paragraph, the pω-K random library was generated
randomizing the central heptad of the K helix by means of mutated primers. The other four
heptads of K peptide maintained the wild type sequence, as done in the case of glycine
mutations, in order to avoid an excessive variability of the whole K helix.
Fig. 2.13 – Scheme of the K-coil randomization: only the central heptad was randomized, while other heptads
retained the wild type sequence.
Due to the degeneration of the genetic code, all amino acids except methionine and
tryptophan are encoded by more than one codon. For example, leucine, serine and arginine are
encoded by six different codons. A degenerated triplet is represented as NNN, where N
indicates any of the four nucleotides.
I Position: A or T or G or C = N
II Position: A or T or G or C = N
III Position: A or T or G or C = N
In order to insert random mutations, the use of degenerated random primers was necessary.
However, with the NNN triplet three stop codons can be casually inserted (TAA, TAG, TGA),
giving a premature arrest of the coil sequence. The codon NNY prevents the selection of
nucleotides A and G, but it excludes three amino acids (methionine, glutamate and glutamine).
This drawback was overcome choosing codon NNK as random triplet, where K stands for the
nucleotides G or T: NNK allows to encode any of the 20 amino acids, avoiding the stop codons,
except for TAG (amber stop). This problem was solved using the E. coli DH5α, a suppressor
bacteria strain that can translate TAG in a glutamine residue.
I Position A or T or G or C = N
II Position A or T or G or C = N
III Position T or G = K
Fig. 2.14 – To insert amino acids randomly, the central heptad sequence was degenerated by using the NNK
codon, that allows to encode any of the 20 natural amino acids avoiding the stop codons, except for TAG.
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Considering the extension and the arrangement of the randomized sequence, the theorethic
number of possible scaffolds is 1,28x109.
3.3 The primers design and construction of pω-Kran library
The PCR was used to generate the library of K random fragments. Given the sequence of
Kwt peptide, primers were designed to obtain a set of K fragments with the central heptad
randomized: as for the construction of glycine-mutated coils, three subsequent cycles of PCR
were performed (see figure 2.15).
With the first cycle of PCR, a mutagenized region was already introduced in the K
fragments. With the second and third amplification reactions, the full K randomized fragments
were generated. Detailed cloning procedure and the primers used are reported in the material
and methods section.
Fig. 2.15 – (A) Schematic representation of the three subsequent rounds of PCR necessary for the
construction of the K random coils. (B) Electrophoresis of PCR products of three amplification rounds: in the
last lane DNA marker, ranging from 100 to 1000 base pairs, is reported.
The figure 2.14-B shows the amplification product for each step. The final step yielded a
PCR product of about 120 bp.
For the construction of the library, both pω vector and K random fragments were digested 
with BssHII and NheI restriction endonuclease. Vector and inserts were ligated, and the ligation
product was used to electroporate DH5α electro-competent cells. Bacteria were subsequently
plated onto six plates with 34 g/ml chloramphenicol, and a little amount was plated on
ampicillin plates to verify the absence of contamination. The ampicillin check is fundamental,
because the presence of contaminants at this level could cause false-positives during PCA.
Dilution were plated onto a small plate with chloramphenicol to assess the size of the library.
After 15 hours of incubation at 30°C, cells were harvested and stocked with 20% of glycerol
at -80°C. The number of independent clones was 108: the result was considered valid and the
library was characterized.
A B 1000 bp
500 bp
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3.4 pω-Kran library characterization
The presence of K random fragments into bacteria was assessed by PCR, performed on ten
clones picked randomly. Generic primers were used, external to the cloning site of pω vector 
(VLPT2/VHPT2)
Fig. 2.16 – Electrophoresis of PCR-amplified insert DNA of 10 randomly picked clones of pω-Kran library.
Each clone, expressing a different cloned Kran fragment, was amplified with VLPT2 and VHPT2 primers.
100bp DNA marker is reported in the last lane.
All clones presented a PCR product of 150 bp. The result here reported confirmed the
integration of K fragments into the pω vector, and the presence into each bacteria of one  pω-
Kran plasmid.
To check the diversity of clones represented in the library, some of them were sequenced to
verify the randomization of the central heptad. Table 2.17 shows that all the sequenced clones
have a different central mutagenized heptad.
Table 2.17 – Four clones of the library were sequenced to check the randomization. In this table the
sequences are compared with Kwt sequence: the residues are completely randomized.
3.5 Selection of the pω-Kran library by PCA
The obtained library is a huge collection of different K fragments with a short randomized
sequence of seven residues. These K random fragments are characterized by a variable stability
when interacting with the wild type E-coil. Again, β-lactamase-based PCA was performed to
select better binding partners to Ewt than Kwt peptides. In this case, the E-coil represents the
wild type peptide, while the K-coil is the new randomized binder. The identification of new
binders took place with two subsequent screenings of the library.
500 bp
1000 bp
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3.5.1 PCA-screening of pω-Kran library
In the first screening, 500 ng of pω-K random library DNA was used to transform pα-Ewt
electrocompetent E. coli DH5α, generating co-transformed bacteria, containing both pα and pω 
vectors. All co-transformed bacteria were equally plated on six plates with 1 mM IPTG and
increasing concentration of ampicillin:
- ampicillin 200 μg/ml;
- ampicillin 400 μg/ml;
- ampicillin 800 μg/ml;
- ampicillin 1200 μg/ml;
- ampicillin 2000 μg/ml;
- 34 μg/ml chloramphenicol, 50 μg/ml kanamycin.
The plates were incubated for 48 hours at 28°C.
Fig. 2.18 – Summary of the first screening strategy: the pω library (pω-Kran in this case) was electroporated
into E. coli DH5α electrocompetent cells. The co-transformed bacteria (8x108) were equally plated onto
agar plates supplemented with antibiotics (chloramphenicol/kanamycin and increasing concentration of
ampicillin).
8x108 pω-Kran/pα-Ewt co-transformed bacteria were obtained. This means that on each plate
more than 108 bacteria were plated. Therefore it was possible to evaluate interactions of all Kran
fragments. Bacteria grown on chloramphenicol/kanamycin plate confirmed the co-
transformation efficiency, whereas on ampicillin substrate bacterial growth was a specific result
of the interaction between Ewt coil and Kran binders.
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Fig. 2.19 – Results of the first-PCA screening of pω- Kran: the graph shows the number of colonies that grew
onto each plate. Any co-transformed bacteria grew onto the chloramphenicol/kanamycin plate; the selective
pressure of increasing ampicillin concentrations allows the growth of .the strongest Ewt/Kran interactor coils.
A decrease in the bacterial growth was observed at increasing concentrations of ampicillin,
that confirms the selective pressure of antibiotic. The number decreased to 26 clones at 2000
μg/ml of ampicillin. The higher the antibiotic concentration, the strongest the E/K affinity was.
Out of 26 isolated clones, six were chosen for a second screening round.
3.5.2 PCA-validation of selected pα-Ewt/pω-Kran clones
With a second screening, the above selected clones were analyzed and compared with the
curve of Ewt/Kwt growth. Our goal was to select the bacterial clone containing the best pair of
interactors. The following pα/pω clones were tested:
- Ewt / Kran 5.11;
- Ewt / Kran 5.12;
- Ewt / Kran 5.17;
- Ewt / Kran 5.32;
- Ewt / Kran 5.40;
- Ewt / Kran 5.44;
- Ewt / Kwt.
The survival ratio of each clone was calculated, comparing the growth rate on
chloramphenicol/kanamycin and on ampicillin plates (from 200 μg/ml to 200 μg/ml). Details of
this method are reported in materials and methods section.
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Fig. 2.20 – Results of the PCA-screening of six clones isolated in the first screening. bacterial growth is
compared with the one of Ewt/Kwt (growth curves actually refer to co-transformant Ewt/Kwt or Ewt/Kran
bacterial clones).
The results reported show that all of these seven clones displayed a better growth curve
respect to the E/K wild type system, according to the data obtained in the first round of
selection. These clones showed a better resistance to ampicillin than bacteria expressing wild
type peptides, with the best performances registered for clones 5.11 and 5.17 (growth on plates
with 2000 μg/ml ampicillin).
This result confirmed the ability of PCA technology to select new coils with improved in
vivo features, in terms of interaction and dimerization.
3.6 Analysis of the expression of selected Kran coils
The production of K random peptides was assessed by western blot assay. The production
was verified:
- in bacteria containing only the isolated pω-Kran: they are named “single clones”,
because they lack of the pα vector;
- in co-transformed bacteria, containing both vectors.
Protein expression was induced in bacteria with 1 mM IPTG at 28°-30°C over night.
As already explained, the recombinant protein “ω domain-Kran” is first produced in the
cytoplasm, and then is translocated into the periplasmic space. The production and the
translocation were verified using both the whole bacterial and the periplasmic lysate. All
samples were loaded in a SDS-PAGE gel, followed by a immunoblot. The recombinant proteins
were analyzed for reactivity to SV5 tag.
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Fig. 2.21 - Western blot assay to check the size and the expression level of randomized K-coils in pω-Kran
single-transformed bacteria. The SDS-PAGE was loaded with both total (TOT) and periplasmic (PP)
fractions of DH5α induced for the expression of the recombinant proteins. The arrows indicate the predicted
molecular weights of the fusion proteins, the dash marks the degradation product. Primary antibody: mouse
anti-SV5 1:2000. Secondary antibody: goat anti-mouse AP conjugated 1:2000.
The pictures show the results for single-clones western blot assay: recombinant proteins
were clearly detected, indicated by arrows. The molecular weight of 19 kDa is the expected one
for Kran/ω-domain chimera (arrows). Two bands were observed for some clones: the upper
band is the correct fusion-protein product, showing the predicted molecular weight, whereas the
lower band is a degradation product (dash arrows).
Fig. 2.22 – Western blot assay to check the size and the expression level of randomized K-coils in pα-
Ewt/pω-Kran co-transformed bacteria. The SDS-PAGE was loaded with total (TOT) and periplasmic (PP)
fractions of DH5α induced for the expression of recombinant proteins. The arrows indicate the predicted
molecular weights of the fusion proteins, the dash marks the degradation product. Primary antibody: mouse
anti-SV5 1:2000. Secondary antibody: goat anti-mouse AP conjugated 1:2000.
In figure 2.22 it has been confirmed that also co-transformant cells correctly express and
process K random coils.
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Chapter 4
Improving the wild type E/K dimer:
the K rational design coils
4.1 Construction of the pω-K rational design library
A totally different approach was adopted to build up the K rational design library, derived
from wild type K-coil. Analyzing the sequence of Kwt, a rational mutagenesis was developed
considering:
1) to mutate amino acids only in specific heptad positions;
2) to employ only few amino acids for the randomization process;
The modifications were performed on all the five heptads, and not only in the central one as
done before. Since the library was constructed with a rational design of K-coil sequence, it was
identified as a library of “K rational design” peptides (Krd).
To this purpose, the pω-Krd library was developed mutating the most important positions of
Kwt heptads for the coiled-coil interaction: a and d (into the apolar core), necessary for
packaging of hydrophobic surfaces, and e and g (external charged residues), important to drive
specificity and stability during heterodimerization. In recent works [106, 138, 149, 179, 215] a
similar rational design approach was adopted, but mutating only one position in the apolar core,
either a or d. In the same way, in this work we kept wild type the residues in the position a
(figure 2.24)
Only amino acids with similar polarity and charge respect to the original residue were
inserted: apolar residues for the hydrophobic core and charged or polar residues for external
surfaces.
- for d: valine, leucine, isoluecine, alanine, methionine and proline;
- for e and g: glutamine, glutamate, arginine, lysine, aspartate, histydine, serine and
asparagine.
Analyzing each codon that translates for desired residues, two degenerate codons were
designed: VYN and VRN.
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Table 2.23 – Degenerate codons designed for the mutation of d, e and g positions.
In this way, each codon combination can translate for any residue on the considered position.
However, with this degenerated codons unwanted amino acids could be produced: glycine
(apolar) in e and g, threonine (polar) in a. Even if these residues carry unsuitable characteristics
for the position they have to cover, these amino acid-encoding codons were retained.
Fig. 2.24 – Schematical representation of the strategy adopted for the rational design of the new library. All
possible residues are listed for red-highlighted d, e and g positions.
The first step for generating the Krd library was the design the suitable primer pairs. Unlike
the construction of Kran library, only a pair of long primers (megaprimers) was used for Krd
fragments. Both primers possess a 3’ sequence homology that allows self-assembly (figure
2.25). To this purpose, it was necessary to conserv the central heptad in order to generate a
primer homology region. In this way, the fragments of the library were obtained keeping the
wild-type central heptad, and randomizing the four lateral heptads.
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Fig. 2.25 - Scheme of the adopted strategy to obtain the full sequence of K randomized fragments: the
sequence of the central heptad was conserved in the wild type form, to allow the annealing between the 3’
ends of the designed primers. BssHII and NheI restriction endonucleases sites are included at the 5’ and 3’
ends of PCR product respectively.
Considering the positions to mutate and the limited degeneration, the theoric number of
different fragments is about 1011, but only 2,17x1010 are the real appropriate scaffolds without
unwanted residues (threonine and glicine).
4.2 The primers design and construction of pω-Krd library
The primers design was performed studying the whole sequence of the Krd peptide and
using degenerated codons. We considered the nucleotide sequence of Kwt (table 2.4)
substituting the codon in the chosen positions with the degenerated codons previously designed.
Table 2.26. – Sequence of the degenerated K rational design coil: the degenerated codons are labeled in red.
Likely to pω-Kran library primers, 5’ BssHII and NheI sites were inserted in the
oligonucleotide sequence.
Figure 2.27 shows the obtained K fragment (about 120 bp): a strong band is visible at the
right size, proving that primers designed were correctly designed ensuring the desired
amplification of Krd fragments.
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Fig. 2.27 - Electrophoresis of the PCR-assembly product of K rational design fragments: 100bp DNA marker,
ranging from 100 to 1000 base pairs, is reported.
The library of Krd fragments and the pω vector were both digested with BssHII and NheI 
restriction endonucleases. Vector and inserts were ligated, and E. coli DH5α competent cells
were electroporated with the ligation product. Bacteria were then plated onto six plates
containing 34 μg/ml chloramphenicol. Also for this library a contamination check was
performed, plating a little amount of cells onto an ampicillin plate. Dilution were plated onto a
small plate with chloramphenicol to assess the size of the library. After 15 hours of incubation
at 30°C, bacteria were harvested and stocked with 20% glycerol at -80°C.
The number of obtained clones was about 107: the library was characterized and tested.
4.3 pω-Krd library characterization
The presence of Krd fragments in bacteria, cloned into pω vector, was assessed performing a 
PCR with generic primers (M13-20/VHPT2) on ten randomly picked clones (figure 2.28)
Fig. 2.28 - Electrophoresis of PCR-amplified insert DNA of 10 randomly picked clones of pω-Krd library.
Each clone, expressing a different Krd fragment, was amplified with M13-20 and VHPT2 primers. 100bp
DNA marker is reported in the first lane.
All clones contained a fragment of the expected size, about 300 bp: the larger PCR size than
Krd peptides was due to external position of the annealing primers employed for the screening.
The results here reported confirmed the integration of Krd fragments into the pω vector, and the 
presence into each bacteria of one  pω-Krd plasmid.
To check the real diversity of the clones of the library, some of them were sequenced,
verifying the randomization of selected residues. The results are reported in table 2.29.
500 bp
1000 bp
1000 bp
500 bp
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Fig. 2.29 – The sequence of four Kran clones compared with the sequence of Kwt coil. The randomized residues are
labeled in red. The central heptad (heptad 3) retains the wild type sequence in all the sequenced clones.
4.4 Selection of the pω-Krd library by PCA
As done for the K random library, PCA was performed also on Krd library to validate new
improved interaction between coils. In this case, the E-coil represents the wild type peptide,
while the K-coil is the new rationally randomized binder. The identification of new binders took
place with two subsequent screenings of the library.
4.4.1 PCA-screening of pω-Krd library
In the first screening, 500 ng of pω-Krd library were electroporated in pα-Ewt E. coli DH5α
competent cells. All transformed bacteria were equally plated onto six plates with 1 mM IPTG
and increasing concentration of ampicillin:
- ampicillin 200 μg/ml;
- ampicillin 400 μg/ml;
- ampicillin 800 μg/ml;
- ampicillin 1200 μg/ml;
- ampicillin 2000 μg/ml;
- 34 μg/ml chloramphenicol, 50 μg/ml kanamycin.
Bacteria were plated on allowed to grow 48 hours at 28°C. 7,2x107 pα-Ewt/pω-Krd co-
transformed bacteria were obtained. This means that on each plate about 1,2 x107 bacteria were
plated. Bacteria grown on chloramphenicol/kanamycin plate confirmed the co-transformation
efficiency, whereas on ampicillin substrate bacterial growth was a specific result of the
interaction between Krd and Ewt coils.
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Fig. 2.30 - Results of the first-PCA screening of pω-Kran library: the graph shows the bacterial growth onto
each plate. Any co-transformed bacteria grew onto the chloramphenicol/kanamycin plate; the selective
pressure of increasing ampicillin concentrations allows the growth of the strongest Ewt/Krd interactor coils.
The results on the graph show that all co-transformed bacteria grew in presence of
chloramphenicol/kanamycin, confirming the presence of both vectors; a decrease in the bacterial
growth was observed at increasing concentrations of ampicillin. At ampicillin 200 μg/ml, 104
clones grew, while the number decreased to 40 clones with 2000μg/m of ampicillin.
Out of 40 isolated clones, seven were chosen for a second round of screening
4.4.2 PCA-validation of selected pα-Ewt/pω-Krd clones
The seven best clones from first screening were analyzed and compared with the growth
ability of Ewt/Kwt clones, with the aim to select the best clone with the best pair of interactors
coils. The following pα/pω clones were tested:
- Ewt / Krd F7;
- Ewt / Krd F8;
- Ewt / Krd F13;
- Ewt / Krd F14;
- Ewt / Krd F24;
- Ewt / Krd F25;
- Ewt / Krd F26;
- Kwt / Ewt.
The survival ratio of each clone was calculated, comparing the growth curve on
chloramphenicol/kanamycin and on ampicillin (from 400 μg/ml to 3000 μg/ml). The data
obtained are reported in the following graph.
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Fig. 2.31 - Results of the PCA-screening of seven clones isolated in the first screening. The bacterial growth
is compared with the one of Ewt/Kwt (growth curves actually refer to co-transformant Ewt/K bacterial
clones).
The reported results show that all seven clones survived to ampicillin 3000 μg/ml with a
better survival ratio than Ewt/Kwt, which were not able to grow at ampicillin 1600 μg/ml. This
final PCA test allow to select four clones: Krd F7, Krd F8, Krd F24 and Krd F26. These K-coils
interact very strongly with Ewt, allowing a stable reconstitution of β-lactamase with a
consequent improved resistance to ampicillin than wild type cognate coils.
4.5 Analysis of the expression of selected Krd coils
The production of K rational design peptides was assessed by western blot. The production
was verified:
- in bacteria containing only the isolated pω-Krd: they are named “single clones”, because
they lack of the pα vector;
- in co-transformed bacteria, containing both pω-Krd/pα-Ewt vectors.
Protein expression was induced in bacteria with 1 mM IPTG at 28°-30°C over night.
As for Kran library, peptides production and translocation were assessed using whole
bacterial and periplasmic lysates. All samples were loaded in a SDS-PAGE gel, followed by a
immunoblot. The recombinant proteins were analyzed for reactivity to SV5 tag, followed by
anti-mouse AP conjugated antibody recognition.
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Fig. 2.32 - Western blot assay to check the size and the expression level of randomized K-coils in pω-Krd
single-transformed bacteria. The SDS-PAGE was loaded with both total (TOT) and periplasmic (PP)
fractions of DH5α induced for the expression of the recombinant proteins The arrows indicate the predicted
molecular weights of the fusion proteins, the dash marks the degradation product. Primary antibody: mouse
anti-SV5 1:2000. Secondary antibody: goat anti-mouse AP conjugated 1:2000.
Recombinant proteins were clearly detected for almost every clone, except for clones F7 and
F24, that showed a lower expression level. Two bands were pointed out for some clones: the
upper band is the correct fusion-protein product, showing the predicted molecular weight (about
19 kDa), whereas the lower band is a degradation product. Some proteins could show an
apparent different molecular weight after SDS-PAGE: this can be ascribed to different
charge/mass ratio of the coils, because the amino acids in d, e and g position of each Krd
fragment are randomized, and they could have different physical characteristics (polarity or
charge).
Fig. 2.33 - Western blot assay to check the size and the expression level of randomized K-coils in pα-
Ewt/pω-Krd co-transformed bacteria. The SDS-PAGE was loaded with total (TOT) and periplasmic (PP)
fractions of DH5α induced for the expression of recombinant proteins. The arrows indicate the predicted
molecular weights of the fusion proteins, the dash marks the degradation product. Primary antibody: mouse
anti-SV5 1:2000. Secondary antibody: goat anti-mouse AP conjugated 1:2000.
The results obtained confirm that also co-transformed bacteria express correctly and
efficiently the new coils. Interestingly, Krd F7 and Krd F24 clones correctly produced Krd
peptides. It is likely that the these Krd proteins expressed in the single-clones bacteria, that can
not interact with Ewt, are highly unstable and rapidly degraded. On the other hand, if the Ewt
coil is present, the interaction stabilizes efficiently avoiding the degradation.
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Chapter 5
In vitro validation of new Kran and Krd coils
5.1 Setup and vector engineering
A fundamental condition for PCA is that the fragments of the reporter protein must not be
able to refold spontaneously. As a consequence, the interactions between the expressed fusion
proteins guide the complementation of the reporter-protein domains, which take place in
periplasmic space. Sometimes a low background signal is present, due to an incorrect protein
folding, to the formation of inclusion bodies and to a low amount of self-complementation of β-
lactamase fragments. These drawbacks decrease the specificity and efficiency of our system.
To check that the interaction between isolated K mutant coils with Ewt coil is not catalyzed
by the two fragments of β-lactamase (but the opposite), mutant and wild-type coils were
produced and purified without the α and ω fragments. Then, in vitro tests were performed to
verify that different conditions than the oxidative environment of the periplasm could allow the
interaction between coils as well. These preliminary tests are fundamental to understand if the
isolated proteins can be used for biosensing applications, where the experimental conditions
can be quite different compared with the in vivo cellular environment.
To this purpose, two different expression vectors were used to produce the mutant coils and
to perform multiple crossed-interaction assays: pMAL-ASC2 and pGEX. Each vector can
express high levels of recombinant protein, which were further purified to decrease the
background due to unwanted protein contaminants.
The pMAL-ASC2 vector is a previously modified version of pMAL-X plasmid, purchased
from New England Biolabs. In the pMAL protein fusion system, the sequence of the protein of
interest is inserted downstream of the MBP (maltose binding protein) cassette, resulting in a
MBP-fusion protein that can be easily purified by affinity purification with maltose or
maltodextrins. The vector includes a sequence recognized by a specific protease, in order to
cleave and separate the protein of interest from MBP after purification, without any further
vector-derived protein residues.
The pMAL-ACS2 vector was previously engineered inserting an AscI restriction site
(compatible with BssHII overhangs), allowing a quick sub-cloning of DNA fragments when the
the restriction endonucleases BssHII and NheI are used. The pMAL-ASC2 carries a SV5 tag for
recognition by anti-SV5 monoclonal antibody, followed by stop codon.
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Fig. 2.34 – Sub-cloning of selected ORF sequence from the pω vector into the expression vector pMAL-
ASC2.
For the same reason (sub-cloning compatibility), the pGEX-4T-1 was previously modified to
obtain a vector with BssHII and NheI sites. The pGEX vectors are members of the GST
(glutathione-S-transferase) fusion system: these plasmids allow the production of recombinant
protein in fusion with GST, which permits a fast and easy affinity purification with glutathione.
Also pGEX vector includes a recognition site for a specific protease (thrombin).
Comparing to the original vector, the polylinker of pGEX contains only BssHII and NheI
sites for restriction endonucleases and the FLAG-tag for the recognition with a monoclonal
antibody.
Fig. 2.35 – Sub-cloning of selected ORF sequence into the expression vector pMAL-ASC2
Into both pMAL-ASC2 and pGEX vectors, the expression of fusion peptides is under the
control of an IPTG inducible promoter, and the presence of a leader sequence, like in p and p
vectors, allows the translocation of fusion proteins into the periplasmic space that can be
quickly extracted from the soluble periplasmic fraction.
The sub-cloning step into these expression vector was performed for the following coils:
Ewt, Kwt, Kran 5.11, Kran 5.17, Krd F8 and Krd F26 (wild type coils plus the best clones of
two libraries PCA-selection). The Kwt and mutant K-coils were readily subcloned, because the
fragments carry the BssHII and NheI restriction sites. The Ewt coil needed an extra engineering
step to insert via primer amplification the appropriate restriction endonuclease sites at the ends
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of Ewt sequence. The coils selected for the production were subcloned and sequenced to check
for the absence of mutations.
Every pGEX and pMAL-ASC2 coil protein was produced and purified with glutathione or
amylose system purification, from 100ml of bacterial culture induced O/N with IPTG. Purified
proteins were subsequently quantified by using both Coomassie gel staining and Bradford
assay: the concentration varied between 0,3 mg/ml and 4 mg/ml. The results of purification
procedure and Coomassie staining are reported in the next picture, where 1μl of each purified
protein was loaded in a 12% polyacrylamide gel (figure 2.36).
Fig. 2.36 – Two 12% polyacrylamide gels loaded with the MBP- and GST-fusion proteins after purification:
loaded 1μl of each purified protein.
Interestingly, the coils cloned into pMAL-ASC2 and pGEX vectors showed a apparently
little differences in molecular weight: as for the pω proteins, this feature can be ascribed to 
differences in peptides sequences and therefore total charge.
To verify whether the ORFs of mutant coils were correctly maintained after the subcloning
step, purified products were analyzed for reactivity to SV5 and FLAG tags in western blot
assay, for MBP and GST fusion proteins respectively. The same amount (1 μl) of the previous
Coomassie was loaded for each protein..
Fig. 2.37 – Western blot assays to assess the correct ORF of MBP- and GST-fusion proteins, subcloned into
the new expression vectors. Primary antibody: mouse anti-SV5 1:2000 (pMAL-ASC2 clones), mouse anti-
FLAG 1:5000 (pGEX clones). Secondary antibody: goat anti-mouse AP conjugated 1:2000.
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5.2 Validation of the system
The validation of the interaction was made through ELISA experiments. Briefly, the GST-
fusion molecules were immobilized on the surface of 96-multiwell plates; after a blocking step
to avoid unspecific interactions, the MBP-fusion molecules were added and the reactivity to
SV5 tag was analyzed after extensive washes. With this assay, only the dimerizing coil pairs can
be detected. The results are reported in the figure 2.38.
Fig. 2.38 – (A) Schematic representation of the ELISA assay: the GST-fusion proteins were firstly coated, the
MBP-fusion proteins were added and the reactivity to SC5 was assessed. (B) The dimers were assayed for
reactivity to SV5 tag: only the dimerizing coil pairs can be detected.
A
B
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GST Ewt GST Kwt GST Kran5.11
GST Kran
5.17
GST Krd
F8
GST Krd
F26 GST
MBP - - - - - - -
MBP Kwt ++ - - - - - -
MBP Kran 5.11 + - - - - - -
MBP Kran 5.17 ++ - - - - - -
MBP Krd F8 ++ - - - - - -
MBP Krd F26 + - - - - - -
MBP Ewt - ++ + ++ ++ + -
Fig. 2.38 - (C) Summary of the interaction: (++) strong interaction, (+) interaction and (-) no interaction. The
red labeled cells are the ones supposed to be positive. The Ewt/Kwt dimer value was set to (++).
The results reported here confirm the reactivity between the selected coils, isolated with the
previous complementation assays. The graph clearly demonstrates how the reactivity was
limited exclusively to the E/K heterodimerization, because the E/E or K/K combinations gave
no signal, ruling out any possible homodimerization process. The Kran 5.17 and Krd F8 coils
showed a comparable reactivity respect Kwt to the Ewt coil, whereas the interaction of Kran
5.11 and Krd F26 to Ewt is lower. MBP and GST proteins were considered as negative control.
In conclusion, the mutated coils represent valid scaffolds for biosensing applications because
they confirmed their specific affinity both in vivo and in vitro; and also that that the
dimerization between the interactors is an active process independent from β-lactamase-
fragments. The lower values obtained in the ELISA of some coils, that in the PCA showed a
good dimerization activity, can be ascribed to the presence of the fusion protein MBP and GST,
and their steric hindrance: further analysis using the coils alone must be accomplished, for
example using the Biacore system.
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Chapter 6
The single chain E-K
6.1 Setup of a biosensor unit: the single chain E-K
In the previous chapters, the structure of E and K coils was analyzed and modified, and the
interaction activity of new peptides was verified with in vivo and in vitro methods (PCA and
ELISA). The interaction was improved, and this allows to conceive customizable biosensors
based on the dimerization of a coiled-coil domain.
The next step of this project was the generation of a new protein scaffold, that can be used
as biosensor unit in many applications. Modifying the sequence of the coils, protein variants can
be generated to bind different specific targets. The main features of a new scaffold must be:
- the capability to bind small molecules;
- small size, for an easy production and use on a biosensor;
- the maintenance of stability in several conditions of pH, ionic force and temperature;
- the construction of a small binding site, composed by few amino acids.
The modification of the central heptad to generate glycine-mutants and the pω-K random
library allowed to isolate and select new peptides with improved binding sites. The next passage
will be the creation of a new E/K coiled-coil domain as a unique fusion protein, with the two
coils covalently linked to each other. The central heptad of both coils will be completely
modified so that the apolar core of the central heptads will become a binding pocket to
accommodate small molecules or compounds.
Starting from the structure of the coiled-coil domain proposed by Chao and coworkers [135,
136], some modification were performed:
1) a linker was inserted between the coils: it is composed by eight residues (seven glycines
and one threonine), that confer a marked flexibility to the whole molecule;
2) the K sequence was inverted, to allow the interaction through a parallel association as in
the original model;
3) one cysteine was inserted in each of the peptide: these residues allow the formation of a
intrachain disulfide bonds, which facilitate the association between coils and stabilize the
scaffold after the modification of the central heptads.
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Fig. 2.39 – (A) Schematic linear representation and (B) three-dimensional model of the single chain E-K (C =
cysteine; 1-5 = coil heptads, which for K are inverted).
The E and K coils, connected by a loop, are able to fold into helical domains and
spontaneously dimerize to form a left-handed super-coil, the single chain E-K (scE-K). This
structure was used to construct a library with a randomization-based mutagenesis of the central
heptads of both peptides, as done for the pω-Krandom library. This randomization was
introduced in order to obtain a huge collection of scaffolds with several different pockets able to
bind different ligands. The randomized library of the scE-K was subsequently cloned into an
appropriate vector to perform a selection based on the phage display technique. The single
chains are presented on the surface of a filamentous bacteriophage, and the selection is carried
out against specific molecules. The main molecule considered in this study was caffeine.
Caffeine is a xanthine alkaloid, that acts as a psychoactive stimulant drug and a mild diuretic
(figure 2.47-A) [216]. It is a stimulant drug of the central nervous system, but if consumed
excessively it could be teratogenic because causes the inhibition of DNA repair and activity of
cyclic AMP phosphodiesterase [217]. Considering the potential harmful effects of caffeine, the
ability to dose it accurately and rapidly could be of particular interest for industrial processes, or
in food and clinical chemistry.
6.2 The pB vector
The first step was the set up of a proper phage display vector for the construction of large
and functional libraries. Generally, phagemid vectors are used for the generation of huge
collections of genes, each of them is under control of an inducible promoter. The presentation
of the peptide of interest on the surface of the phage is guided by its expression in conjunction
with the g3p surface protein, in the form of a recombinant polypeptide. The vector used for the
scE-K library was the phagemid vector pB, consisting of the following cassettes:
- the origin of replication (ORI);
- a polylinker site at the upstream of the g3p phage ORF;
- the inducible lacZ promoter, to control the expression of the scE-K;
- the ORF encoding for the g3p;
- the leader sequence to control the correct secretion into the periplasmic space;
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- the ORF encoding β-lactamase for antibiotic selection;
- the wild type sequences of E and inverted K-coils (see above paragraph);
Fig. 2.40 – (A) Schematic representation of pB vector. The expression of single chain E-K is under the
control of a Lac promoter; the translocation into the periplasmic space is under the control of the PelB leader
sequence. (B) Phage particle displaying the single chain E-K in fusion with the gene 3 protein (g3p).
6.3 Construction of pB scE-K library
On the basis of the advantages deriving form the use of phage display, an single chain E-K
library was created using a phagemidic vector. The randomization of the central heptad of each
coil allowed to create a collection of single chains able to bind different ligands. In fact, each
single chain has a different binding pocket with different ligand affinities.
Considering the extension and the available residues for randomization, the number of
possible scaffolds was 1,63x1018. In fact, one heptad was randomized in each coil, and two
modified coils had to match each other. However, this variability is too much high to be
obtained with this technique.
Once having detected the vector, the next step was the design of correct primers to generate
the library by PCR amplification of fragments. As explained in paragraph 6.1, the target regions
for randomization were the central heptads of both E and Kinv coils.
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Fig. 2.41 - Schematic representation of the PCR rounds necessary for the construction of inverted Kwt and
Ewt randomized coils. The red rectangle highlights the shared sequence included with the last round of
amplification: this shared sequence was exploited to assembly the PCR products, generating scE-K library.
The modification was introduced using the same strategy applied to obtain the pω-K random
library, mutating randomly each position into the central heptad (a-b-c-d-e-f-g) with the aid of
degenerated primers (NNK triplets). The library was created by assembling Kinv and E
randomized coils in the single chain format.
The pool of PCR fragments and the pB vector were both digested with BssHII and XmaI
restriction enzymes. After purification, fragments and vector were ligated, and the ligation
product was used to electroporate E. coli DH5α competent cells. Bacteria were subsequently
plated onto six ampicillin plates. After 15 hours of incubation at 37°C, cells were harvested and
stocked with 20% glycerol at -80°C.
The extension of the library was 2x108 independent clones. This result did not assure the
presence of all possible single chains, but the size was considered satisfying for this technique,
and it was analyzed for subsequent rounds of selection.
6.4 pB scE-K library characterization
The diversity and integrity of this library was tested in several ways. First of all, more than
20 single chain E-Ks were tested by PCR from randomly selected bacterial clones. This showed
that 21 clones contained a full length insert, while 5 of them were deleted.
500 bp
1000 bp
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Fig. 2.42 - Electrophoresis of PCR-amplified scE-K DNA of 26 randomly picked clones. Each clone,
expressing a different scE-K fragment, was amplified with K2-PCR-sense and E1-PCR-anti primers. 100bp
DNA markers, ranging from 100 to 1000 bp, are reported.
Furthermore a sequencing of 12 clones was necessary to check the diversity of the library,
because a fingerprinting test was impossible to perform for the small size of randomized heptad.
Clone Kinv (centralheptad)
E (central
heptad) K sequence E sequence
1 WT Ran E K L A S V K V L T W W P L
2 Ran Ran L L L G R R S L R N S R Y Y
3 Ran Ran P G G L R R W R A F P S I R
4 WT Ran E K L A S V K S F L Y V F W
5 Ran Ran F L T L A R I S W K S Y V Y
6 Ran Ran L L I C L G G A V V W V S E
7 WT Ran E K L A S V K R S G M K L K
8 Ran Ran S L V G G N W Q C G V F V F
9 Ran Ran P S S V G F C C V V K M V F
10 Ran Ran C F R W M V F D L L G G I I
11 Ran Ran V L L F D M R F V C F G T W
12 Ran Ran V F Q C V L G R A C S L V C
Table 2.43. – Summary of the randomized-central heptad sequencing of 12 scE-K clones. Three single chains
carry the wild type sequence of the inverted K-coil (in bold).
The table above shows that 3 clones out of 12 have a wild type K-coil and a E-coil with the
central heptad correctly randomized. The other clones possess both randomized peptides. This
library was then used for standard phage display selection steps.
6.5 Selection of the phage display library
6.5.1 Description of selection approach
To select and isolate a single chain-expressing clone, the ligand of interest must be first
coated on surface. The coating can be realized in two different ways::
1) using the biotin-streptavidin method;
2) with direct immobilization on an active surface able to bind amino groups.
The molecules used for the selection carry a linker sequence as a spacer between the coating
surface and the real ligand. The linker carries a biotin molecule or a free amino group at one
extremity, depending on the selected coating method. The first method needs a preliminary step
for streptavidin immobilization onto a surface, after which, the biotinylated-ligand tightly binds
to immobilized streptavidin.
Several cycles of selection with different protocols were performed to determine the best
selection method (data not shown). On the basis of the results obtained in the preliminary
experiments, a series of selections were programmed with an additional pre-incubation step. The
library was incubated with the non-coated surface and binding buffer without the ligand of
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interest: this passage was introduced to avoid the selection of unspecific clones, removing them
from the phage population.
6.5.2 Selection of the pB scE-K library by magnetic beads
Several selection strategies were tested: the use of paramagnetic beads allowed to isolate
positive clones during preliminary selections, demonstrating a good experimental performance.
The selection strategy is depicted in figure 2.44.
Fig. 2.44 - Selection strategy used to select phages reactive to biotinylated caffeine: (1) functionalization of
magnetic beads with the biotinylated caffeine; (2) incubatation with phages: reactive phages (labeled in red)
bind the caffeine; (3) application a magnetic field to separate the non-reactive phages; (4) extensive washes to
remove unbound phages; (5) elution of the reactive phages.
This selection methods can be reassumed in 5 steps:
1. pre-coating of magnetic beads with streptavidin, and incubation with biotinylated-
ligand;
2. incubation of phages with the beads;
3. application of a magnetic field to collect beads bound phages;
4. extensive wash passages to remove unbound phages;
5. elution of bound phages by competition with pure, non-biotinylated ligand.
For each round of selection, 1012 phages were resuspended in 250 μl of PBS. Phages were
then pre-incubated with 2% non-fat milk (MPBS, the buffer used for the selections) to remove
non-specific single chains expressing phages. Then, they were incubated in a mixture containing
biotinylated caffeine bound to paramagnetic streptavidin-coated beads and shaked for 30’. After
extensive washes with PBS / 0,1% Tween (PBST) and PBS (to remove all unbound and
unspecific phages), elution was performed incubating beads for 30’ with a 100 μg/ml solution of
caffeine without linker nor biotin..
After this selection, 9 ml of DH5α at OD600nm 0.5 were infected with the recovered phages, at
37°C for 45’.Bacteria were then plated and allowed to grow over night. The day after, bacteria
were harvested and stocked at -80°C in glycerol. A small aliquot was immediately let to grow in
order to produce new phages for a second round of selection. Four passages of selections were
carried out, with increasing stringency of washing steps.
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Fig. 2.45 – Input and output values for each round of selection.
For each step, an input of approximately 1012 phages was used . However, the final output of
phages during the second round of selection was remarkably lower than the first one. This
decreased number of recovered phages is a direct result of the increased stringency of the
selection procedure. The third and fourth cycles maintained a high yield of recovered phages,
probably because of the amplification of the previously selected clones.
6.6 Validation of selection strategy
After the fourth round of selection, 86 individual phage clones from the selected population
were tested by phage ELISA against their specific antigen (biotinylated caffeine), and
streptavidin, excluding any non specific reactivity. Out of these 86 clones, at least six showed a
good reactivity to caffeine, but with a detectable reactivity with streptavidin. In order to reduce
the background due to unspecific interactions, the PBS Tween 0,3% was used as buffer (figure
2.46).
Fig. 2.46 – Reactivity of the previously isolated clones to caffeine, streptavidin and PBST 0.3%. The positive
control was a reactive single chain, previously isolated; the negative control was the single chain E-K with
the wild type coil sequence. Secondary antibody: anti-M13 HRP conjugated 1:2000.
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These experiments demonstrated that there was specific interaction between the single chains
in fusion with g3p protein of phages and caffeine, even if there is a still low detectable reactivity
against streptavidin. To verify that the six selected clones were specific only for caffeine
molecule, they were analyzed searching for a putative reactivity against menthone (a
structurally related molecule) or to the biotinylated linker alone, to rule out its possible
involvement in ligand-coil interaction. :
The results obtained with this assay confirmed that the isolated single chains are merely
specific for caffeine: they interact with high affinity and high specificity with the ligand of
interest, excluding any unwanted cross-reaction (figure 2.47).
Fig. 2.47 – (A) Structure of biotinylated caffeine and menthone. (B) Reactivity of the isolated clones to
caffeine, menthone, biotinylated linker and PBST 0.3%. The single chain E-K with the wild type coil
sequence was considered as negative control. Secondary antibody: anti-M13 HRP conjugated 1:2000.
A second further validation to ensure the specificity of interaction between single chains and
caffeine was done by using NUNC Immobilizer wells. These plates posses surfaces coated with
a photoprobe consisting of electrophilic groups that can rapidly form a covalent bond with
nucleophilic groups, like amines: their density is optimized for immobilizing peptides and
proteins. NUNC plates allow the direct immobilization of proteins on ELISA wells, avoiding
the use of streptavidin and also minimizing steric hindrance to optimize binding interactions.
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The molecule of caffeine was modified to facilitate a covalent bond on NUNC Immobilizer
wells and biotin was replaced by a reactive amino group. The buffer used for each step was PBS
Tween 0,3%.
Fig. 2.48 - Reactivity of the isolated clones to caffeine, immobilized onto NUNC Immobilizer wells by using
a reactive amino group. The positive control was a reactive single chain, previously isolated; the negative
control was the single chain E-K with the wild type coil sequence. Secondary antibody: anti-M13 HRP
conjugated 1:2000.
The results reported here finally show that values obtained with biotin-ligand molecule were
independent from the linker sequence and from the streptavidin used for immobilization of
biotinylated caffeine.
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Discussion
In the last years the development of highly sensitive biosensors has considerably increased.
In fact, the need of bioanalytical devices has gained importance for several applications, such as
healthcare, diagnostics, food quality, drug delivery, environmental monitoring and many other
research fields [2, 4, 218]. The demand is centered on small-size biosensors characterized by
high sensitivity, high specificity and good accuracy for fast and reliable results.
Nanotechnology is revolutionizing the development of new biosensors, based either on the
improved proprieties of new materials, or on the proprieties that standard materials show only at
nanoscale. Miniaturized platforms allow to broaden the potential applications of bioanalytical
devices, providing new reliable instruments that are cheaper, easier to use and, above all,
smaller [8, 15]. The production of systems with high multiplexing potential is one of the most
important aims in bio-nanotechnology research, allowing the integration of many sensors in one
single platform. Nanotechnologies can help to produce biosensors with great advantages, such
as the need of small sample volumes, that allows in the detection of biomolecules even at very
low concentrations.
Engineered antibodies are currently the most widespread detecting tool for biotechnological,
medical and pharmaceutical applications, because of the deep knowledge of their structure,
binding capabilities and specificity of action. However, the emerging field of protein
engineering allowed the production of a wide range of scaffolds different than antibodies, with
various origins and characteristics, for protein library construction and for grafting experiments
of binding sites [79, 80]. The proprieties of these new scaffolds are quite similar to the ones
characterizing antibodies, i.e. specificity and affinity, but some features are improved, like a
reduced size (the smaller scaffold is the knottin Min-23, only 23 amino acids), a binding pocket
restricted to few residues and a good stability even without disulfide bonds. All these
characteristics are suitable to create a customizable nanotechnological device with enhanced
spatial resolution, that can be further improved to construct biosensors-based detecting system
for any application.
A biosensor is defined as an analytical device that converts the energy released during
binding between molecules into an electrical signal. The binding substrate is often of biological
nature, therefore the choice of proper molecules to be used as recognition unit is fundamental.
The miniaturization of the detecting system requires the employment of small molecules, and
new scaffold proteins are the most promising tool for this purpose: the increasing knowledge of
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their structure, and the wide potential of site-specific modifications on demand, allows to
develop platforms of high scientific and commercial impact.
The aim of this work was the development and the improvement of new scaffold proteins for
biosensing applications, and to this purpose two biological methods have been adopted: the
protein complementation assay (PCA) and the phage display. In fact, we have demonstrated
how they could represent a powerful selection tool and could offer a reliable help for the
production of novel biosensors for environmental survey, biomedical applications and for every
case in which high sensitivity and specificity are requested.
In the last five years many scaffolds have been taken in consideration for different purposes,
sometimes replacing antibodies [85]. Each scaffold has well-defined features and properties that
can be easily modified or even improved , in order to confer it an adequate flexibility in terms of
application potential. For all these reasons, coiled-coil based scaffolds are recognized among the
most promising instruments in the biosensor field [137]. This domain is present in a variety of
proteins involved in different cellular processes, about in the 10% of the total proteins expressed
by a single cell. Its peculiar structure has been extensively studied to characterize the
dimerization dynamics and overall the tolerance to sequence modification, a fundamental pre-
requirement to use coiled-coils as biosensor units.
In fact, the possibility to modify the amino acid sequence allows the improvement of binding
features. Considering their characteristics, coiled-coils have been used as affinity purification
tags, library presentation scaffolds and as bases for the creation of miniantibodies [114, 148]
To this purpose, this work has focused the attention on a de novo heterodimeric coiled-coil
domain, named E/K. Starting from typical features of coiled-coil containing proteins, Tripet and
Chao [114, 136] were able to design de novo this heterodimeric system. E and K peptides
consist in a single amino acid heptad repeating five times: the hydrophobic residues in the
apolar core and the charged residues on the external surface allow the strong interaction
between them to forma unique right-handed super-coil. The physical-chemical proprieties of the
domain have been deeply analyzed with circular dichroism to assess the high binding affinity
and the remarkable thermal and chemical stabilities. All these proprieties render the E/K system
an ideal base to create functional biosensors. Moreover, the hetero-dimerization capability is a
positive feature that allows to combine different E and K peptide to produce customizable
platforms.
In the present work, the stability of E/K coiled-coil domain was tested with protein
complementation assay, in order to validate in vivo the data obtained with circular dichroism.
Additional modifications and experiments were performed with the final aim of improving the
interaction between the coils, in order to create E/K pairs with increased binding affinities or
recognition of new specific ligands.
The first step was the in vivo validation of the E/K interaction system by using the cprotein
complementation assay [170]. As previously described, PCA is based on a reporter protein
rationally dissected into two subunits, unable to refold spontaneously, that are fused to two
proteins that are thought to bind to each other. The refolding of the reporter protein from these
fragments is catalyzed by the binding of the two supposed interactor proteins, and is detected as
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reconstitution of its enzymatic activity. In this work, the use of PCA based on β-lactamase was
described and extensively used, and the interaction among the proteins was easily detected by
the bacterial growth on ampicillin-supplemented broth. The pα and pω vectors were used to 
allow the expression of proteins fused to α and ω fragments of the β-lactamase.
The Ewt and Kwt coils were expressed by the pα and pω vector, respectively. The growth 
rate of bacteria expressing these peptides was compared to control cells deficient for antibiotic
resistance (negative control) and to cells constitutively expressing a wild-type β-lactamase
(positive control), in order evaluate any differences in enzymatic activity between wild-type and
reconstituted β-lactamase. We first confirmed that only bacteria containing interactors can grow
on selective pressure conditions, and no growth was observed for cells expressing proteins that
were not able to interact. Even if the reconstituted enzyme in Ewt/Kwt expressing bacteria
displayed a reduced hydrolytic activity than intact-enzyme strains, the growth rate on different
antibiotic concentrations was anyhow considered acceptable
The results obtained in these assays provide the demonstration that β-lactamase-based PCA
is a reliable method to evaluate protein-protein interactions: the results derived are in good
agreement with previous results obtained with circular dichroism.
When developing a biosensor, one has to take in consideration the use of highly stable
molecules that do not change their properties in presence of extreme conditions, such as
low/high pH, temperature and ionic strength, conditions that are often required for the storage
or usage of a biosensor unit. This is why a major goal of this work was the selection of resistant
E/K interactions able to tolerate extreme experimental settings. Any alteration of stability
requires an alteration of the coil domain, that, however, needs to maintain its basic folding.
Therefore, before the selection of new coiled-coil interactors we verified that this E/K domain
effectively represents a protein scaffold, able to tolerate amino acid substitutions without
altering its main structure.
First of all, glycine substitutions were performed, and the ability of mutated peptides to form
helical coils as well as the quality of this novel interactions was verified trough PCA.
Theoretically, glycine insertion would lead to the severe impairment of the propensity to form
helical coils, resulting in loss of E/K interaction. Our results clearly demonstrate not only that
the E/K system tolerates sequence modifications, but also that the K-coil is more resistant to
mutations showing an interaction capability even superior to wild type peptides. Therefore, this
coil can be fully qualified as protein scaffold and PCA could be considered a valid methodology
to select and validate proteins with scaffolding characteristics.
Once having demonstrated that the K-coil is more prone and resistant to sequence
modifications than E-coil, we created two K-mutant libraries and selected mutants displaying
improved interaction properties, as done in several other studies concerning different proteins
[106, 149, 180]. The mutations were introduced by randomization either on the central heptad of
K-coil, to generate K random library (Kran), or on the whole helix with a rational approach (i.e.
mutation of crucial residues for dimerization, introducing selected amino acids), to generate a K
rational design library (Krd). From these two libraries we selected and isolated bacterial clones
expressing mutated K-coils displaying improved binding affinity to Ewt than the Kwt peptide.
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All these interactions allowed bacterial survival even at high antibiotic concentrations, in some
cases in prohibitive conditions for Ewt and Kwt expressing cells
The isolation of coil variants with better affinity and stability than the original ones is a clear
demonstration of how the combination between structural modification of proteins and PCA
allows a fast end effective way to select interactors with desired properties, but still retaining the
original, native coiled-coil structure. The same strategy could be applied also for E-coil, even if
it has demonstrated to be more instable when glycine residues were inserted into the sequence.
In this way we can progressively create a new coiled-coil dimer with improved interaction
capability or ligand affinity for different applications.
Moreover, PCA and site directed mutagenesis can be rationally employed to characterize
protein-protein interactions and map the domains involved in this phenomenon. In this way, not
only a map of protein networks can be created (interactome), but also a fine characterization of
the subdomains involved.
These coils will be finally employed on bioanalytical platforms, therefore outside the natural
cellular environment: for this reason is necessary to evaluate the activity of E and K coils in an
isolated in vitro environment. Chimeric coils have been purified from selected bacterial clones,
and used for ELISA tests. The high interaction selectivity seen in vivo has been confirmed also
in vitro: on one side, homodimerizations were not detected, on the other, the specific
interactions between E and K peptides were measured as well. However, none of the
interactions between mutated K-coils and wt E-coil displayed better interaction ability respect to
wt peptides. This result is in conflict with in vivo evidences, because the same mutated K-coils
conferred a better antibiotic resistance than Kwt-expressing bacteria (i.e. better β-lactamase
activity deriving from better coiled-coil interaction).
These contrasting data can be ascribed to a different stability or impaired binding propensity
between coils because of the experimental conditions used during ELISA tests (for example
ionic strength or pH). Moreover, for in vitro assays, E and K peptides were purified as GST and
MBP fusion chimeras: these tags might potentially interfere with the correct folding of E and K
coils, resulting in a loss of signal.
Finally, to correctly evaluate the improvements of the interaction affinity of this system,
other methods such as Biacore. The Biacore biosensor can measure protein-protein interaction
and binding affinity of unlabeled interactors in real time, obtaining the individual association
and dissociation rate constants.
The dimerization propensity and tolerance to sequence modifications of a coiled-coil system
allowed us the construction of a new scaffold structure able to bind small molecules, with
several analytical implications. This new structure based on E and K coils has been engineered
to generate a single molecule containing both peptides, the single chain E-K (scE-K).
During this project we created an scE-K library, based on the randomization of the central
heptad to allow the recognition and the binding of small molecules. The library contamination
with Kwt coil was not considered critical, because the totality of E-coils were mutated, still
allowing the creation of a binding pocket.
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Phage display methodology [193] was used to isolate single chains reactive with the desired
analyte, caffeine. Thanks to this technique, the single chain library was expressed in fusion with
a surface capsid protein, and after several selection cycles we isolated single chain mutated
peptides carrying a binding pocket highly specific for caffeine. We chose this molecule because
it is small, easy to handle and of particular interest for industrial processes, or in food and
clinical chemistry [216].
The selection process was carried out on magnetic beads that displayed a good functionality
in preliminary experiments (data not shown): a pre-selection step was performed to clean out
phages that unspecifically cross-reacted with the magnetic support or the buffer employed for
the selection. Clones were then selected for a specific reactivity against caffeine, and the
interaction was validated using a strictly related molecule (menthone) that was not recognized
by caffeine reactive phages. This technique offers a high potential of selection of clones reactive
against any desired molecule or compound, from toxins to heavy metals to diagnostic markers,
because each library virtually contains any possible combination of mutated E and K peptides
able to bind a wide range of molecules. One other advantage is that with the aid of phage
display one can directly select protein scaffolds able to bind the analyte of interest bypassing
time-consuming 3D modeling of interactions between coils and ligand. Moreover, this
technique could be potentially applied to any other protein scaffolds based library.
The selection techniques employed in this research project have demonstrated to be valid and
effective to evaluate molecular interactions and isolate protein interactors with features suitable
for biosensing applications. In fact, an analytical platform containing a biological component is
highly reliable because it is based on the extreme specificity of interaction between the
“sensor” and the compound of interest (for example between antibody and antigen). In our case,
both E/K single chains and K mutant coils can be immobilized on nano-platforms like
nanoarrays for the employment in all those biotechnological applications that require
miniaturization and high sensitivity and specificity. Moreover, the advances in the field of array
printing (see chapter 1.6) have notably ameliorated the production of nano-platforms: the recent
techniques (e.g. PISA, NAPPA and DAPA) allow the in situ co-transcription/translation of
DNA products in proteins [69]. This feature enables the rapid, economic and “on demand”
creation of biosensors, maintaining their properties unaltered, without needing to purify the
molecules to be immobilized, as the ones isolated and characterized in the present work.
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Materials and methods
Abbreviations
AP, alkaline phosphatase
APS, ammonium persulfate
BCIP, 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside
B-PER, bacterial protein extraction reagent
BSA, bovine serum albumine
DMSO, dimetilsulfoxide
dNTPs, deoxynucleotides
DTT, dithiothreitol
HRP, horseradish peroxidase
IPTG, isopropyl β-D-1-thiogalactopyranoside
MW, molecluar whieghts
NBT, nitro-blue tetrazolium
O/N, over night
PEG, polietilenglicole
PPB, periplasmic buffer
RT, room temperature
SDS-PAGE, dodium dodecyl sulphate - polyacrylamide gel electrophoresis
TMB, tetrametilbenzidine
tTG, tissue transglutaminase
Solutions and buffers
 Phosphate buffered saline (PBS)
8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4 in 1000 ml H2O, final pH 7.4.
 Phosphate buffered saline Tween 0.1% (PBST)
PBS added with 0.1% Tween 20
 Milk Phosphate buffered saline (MPBS)
PBS added with 2% non-fat milk powder.
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 2XTY liquid broth for bacteria
6.4g Bacto-tryptone, 4g Extract Yeast, 2g NaCl, H2O in 400 ml H2O. If required ampicillin
0.1 mg/mL, kanamycin 0.05 mg/m, 0.034 mg/ml chloramphenicol.
 2XTY Agar plates
6.4g Bacto-tryptone, 4g Extract Yeast, 2g NaCl, 6g Bacto-Agar in 400 ml H2O. If required
ampicillin 0.1 mg/mL, kanamycin 0.05 mg/m, 0.034 mg/ml chloramphenicol.
 TAE buffer for DNA electrophoresis on agarose gels
0.04 M Tris-acetate, 0.001 M EDTA.
 Loading buffer 6x for DNA samples (agarose gel)
40% glicerol, 60% H2O, 0.10% (w/v) bromophenol blue.
 SDS Running Buffer for protein electrophoresis on acrylamide gels
25 mM Tris, 250 mM glicin, 0.1% SDS pH 8.3.
 Loading buffer 2 for protein samples
100mM Tris pH 6.8, 4% SDS, 0.2% bromophenol blu, 2% β-mercaptoethanol, 20%
glycerol
 Running gel for SDS-polyacrylamide gel
12% polyacrylamide mix (29% acrylamide, 1% bisacrylamide), 0.375M Tris pH 8.8, 0.1%
SDS, 0.1% APS, 2 μl TEMED (N,N,N',N'-Tetramethylethylenediamine), H2O to 10 ml.
 Stacking gel for SDS-polyacrylamide gel
5% polyacrylamide mix (29% acrylamide, 1% bisacrylamide), 0.125M Tris pH 6.8, 0.1%
SDS, 0.1% APS, 1 μl TEMED (N,N,N',N'-Tetramethylethylenediamine), H2O to 4 ml.
 Loading buffer 2x for protein samples (acrylamide gels)
100 mM Tris pH 6.8, 4% SDS, 0.2% bromophenol blue, 2% β-mercaptoethanol, 20%
glycerol.
 AP buffer
Tris 1M pH9,5, NaCl 100mM, MgCl2 5mM
 Lysis buffer
20 mM Tris pH 8.00, 500mM NaCl, 0,.1% Triton x100
 TSS for preparation of competent E. coli cells
85% 2xTY, 10% PEG mw 8000, 5% DMSO, 50 mM MgC12. Filtration with 0.2 μm filter
 Glycerol buffer for preparation of electrocompetent E. coli cells
10% glycerol in milli-Q H2O. Autoclave before use.
 PPB for extraction of periplasm fraction
200 mg/mL Sucrose, 1mM EDTA, 30 mM TrisHCl pH 8.0.
Bacterial strains
The bacterial strains used in this study were:
- Escherichia coli DH5αF’ (Gibco BRL), F’/endA1 hsd17 (rK-mK+) supE44 thi-1 recA1
gyrA (Nalr) relA1 _(lacZYA-argF) U169 deoR (F80dlacD-(lacZ)M15);
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- Escherichia coli BL21-CodonPlus-RP strain: B F– ompT hsdS(rB– mB–) dcm+ Tetr gal
endA Hte (rgU proL Camr);
Oligonucleotides
All primers were purchased from Tib Molbiol – Roche.
Name Sequence
Kwt-sense
ctc tag cgc gca tgc caa agt aag cgc tct caa gga aaa
ggt atc cgc gct taa aga gaa ggt atc tgc act caa gga
g
Kwt-anti tga ctg cta gcc tct ttc agt gcg ctc act ttc tct ttgaga gca gaa act ttc tcc ttg agt gca gat ac
Ewt-sense Ctc tag aat tcg aag tta gtg cgc tgg aga agg agg ttagcg ctc ttg aga aag agg tat ccg cgc tcg aaa aag ag
Ewt-anti tga ctg cta gcc ttc tca aga gcg ctc act tcc ttt tcaagc gca gaa acc tct ttt tcg agc gcg gat acc tc
E-mutgly-sense gcg ctt aaa gag ggc ggc tct gca ggt ggt gag aaa gtttct gct ctc
E-mutgly2-sense gaa gtt agt gcg ctg gag aag gag gtt agc gct ctt gag
E-EcoRI-sense agt cga att cga agt tag tgc gct gga g
E-HindIII-anti agc tca agc ttt act tct caa gag cgc tca c
K-mutgly-sense gcg ctt aaa gag ggc ggc tct gca ggt ggt gag aaa gtttct gct ctc
K-mutgly2-sense aaa gta agc gct ctc aag gaa aag gta tcc gcg ctt aaagag
K-BssHII-sense ctc tag cgc gca tgc caa agt aag cgc tct caa g
K-NheI-anti tga ctg cta gcc tct ttc agt gcg ctc ac
Egly-sense gcg ctt aaa gag gga gga ggt gga ggt gga ggt gag aaagtt tct gct ctc
Kgly-sense gcg ctt aaa gag gga ggt gga ggt gga ggt gag aaa gtttct gct ctc
Kmut1-sense gta tcc gcg ctt aaa gag nnk nnk nnk nnk nnk nnk nnkaaa gtt tct gct ctc
VHPT2 tgg tga tgg tga gta cta tcc agg ccc agc agt ggg tttg
VLPT2 tac cta ttg cct acg gca gcc gct gga ttg tta tta ctc
K-deg sense act ggc gcg cat gcc vrn gta agc gct vyn vrn gaa vrngta tcc gcg vyn vrn gag aag gta tct gca ctc aag gag
K-deg-anti atg cgc tag cct cny bnr btg cgc tca cny btt cny bnrbag cag aaa cny bct cct tga gtg cag ata c
M13-20 gta aaa cga cgg cca gtg
E-BssHII-sense act ggc gcg cat gcc gaa gtt agt gcg ctg gag
E-NheI-anti ctg agc tag cct tct caa gag cgc tcac
K-inv-sense
agt cgc gcg cat gcc gag aaa ctg gca agc gtg aaa gag
aaa ctc gct tct gtt aaa gag aag ctc gca tct gta aag
gag
K-inv-anti atg cgc tag ctt tta cgc tag cga gct ttt cct tta cggacg caa gtt tct cct tta cag atg cga gct tct c
K1-PCR-sense aaa gag aaa ctc gct tct gtt aaa nnk nnk nnk nnk nnk
Materials and methods
98
Table 3.1 – Sequences of all oligonucleotides used in this work
Experimental methods
PCR (Polymerase Chain Reaction)
The proof-reading Phusion Pyrococcus-like DNA polymerase (Finnzymes) was used for
construction of coils sequences and the libraries.
Reaction mixture:
 Template DNA 0.01-1 ng (plasmidic DNA)
 Sense primer 0.5 pmol/μl
 Antisense primer 0.5 pmol/μl
 Phusion HF Buffer 5x
 dNTPs (Sigma) 0.25 mM
 Polymerase 0.025 units/μl
 H20 to 50 μl
The following cycles were performed:
 Denaturation step, 30’ at 98°C.
 31 cycles of: denaturation, 15’’ at 98°C; annealing, 15’’ at 60°C; elongation, 30’’ every
1000bp at 72°C.
 Final elongation step: 10’ at 72°C.
Thermus termophilus DNA polymerase (Biotools) was used to validate the cloning steps.
Reaction mixture:
 Template DNA 0.01-1 ng (plasmidic DNA)
 Sense primer 0.5 pmol/μl
 Antisense primer 0.5 pmol/μl
 Biotools Buffer 10x
 dNTPs (Sigma) 0.25 mM
 MgCl2 2 mM
 Polymerase 0.025 units/μl
nnk nnk gag aaa ctt gcg tcc gta aag
K1-PCR-anti tga cta ccg gta ccg cct ccg cct ttt acg cta gcg ag
K2-PCR-sense ctc tag cgc gca tgc cgc gtg cgg cgg aac tag tga gaaact ggc aag c
K2-PCR-anti cgc act aac ttc acc ccc acc ggt acc gcc tcc gcc
E1-PCR-sense gtt agc gct ctt gag aaa nnk nnk nnk nnk nnk nnk nnkgag gtt tct gcg ctt gaa
E1-PCR-anti tga ctt cta gac ccg ggg cag ccg cca cca ccc ttc tcaaga gcg ctc ac
E3-PCR-sense acc ggt ggg ggt gaa gtt agt gcg
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 H20 to 20 μl
The following cycles were performed:
 Denaturation step, 5’ at 94°C.
 31 cycles of: denaturation, 45’’ at 94°C; annealing, 45’’ at 60°C; elongation, 1’ every
1000bp at 72°C.
 Final elongation step: 10’ at 72°C.
DNA electrophoresis on agarose gel
Agarose (Sigma) gels with a concentration of 2-1,5% in TAE buffer were used to separate
PCR products; 0,8% agarose gels were used to separate plasmidic DNA preparations. 1μl of
ethidium bromide (Sigma) was added to 30 ml of solution. 100 and 1000 base-pairs molecular
weights were purchased from Fermentas.
DNA purification
The GenElute Gel Extraction Kit and GenElute PCR Clean-up kit (Sigma) were used for
purification of DNA agarose gel and reaction mixtures respectively, following the instruction of
the manufacturer.
The NucleoTraP CR (Machery-Nagel) was used for purification of mixtures of libraries
ligations.
DNA digestion with restriction endonucleases
All restrictions endonucleases (BssHII, NheI, EcorI, HindIII, XmaI, AscI) were purchased
from New England Biolabs.
Reaction mixture:
 DNA;
 NEB buffer 10x;
 BSA 100x (if necessary);
 Restriction endonuclease, 1unit/ug of DNA;
 H2O to 50 μl.
The incubation was performed at the temperature required by the specific enzyme.
DNA Ligation
Vector and insert DNA were mixed at the experimental-required ratio, as number of
molecules (1:3 – 1:5). T4 ligase from New England Biolabs was used:
Reaction Mixture:
 DNA
 T4 ligase buffer (NEB) 10x;
 T4 ligase (NEB), 1 unit;
 H2O to 15 ul;
Incubation O/N at 16°C.
Plasmidic DNA extraction
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The GenElute Plasmid Miniprep (Sigma) was used for plasmidic DNA mini-preparations,
starting from 1-5 ml of bacteria culture, and following the instruction of the manufacturer.
DNA sequencing
PCR products were purified with Eppendorf Perfectprep Gel Cleanup kit. Reaction mixtures
for sequencing was composed as follows:
 50-100 ng of purified PCR product;
 1 μl primer (3,2pmol/μl);
 2 μl Terminator Mix (Applied Biosystems, BigDye Terminator v1.1 Cycle Sequencing
Kit);
 2 μl buffer 5x;
 H
2
O to 10 μl;
and the sequencing program was:
 1’ at 96° ;
 25 cycles: 15’’ at 96°; 5’’ at 50°; 4’ at 60° ;
Reactions were afterwards purified with CENTRI SEP Spin Columns, following
manufacturer instructions. 5 μl of purified sequences were loaded on sequencing plates with 10
μl of formamide, denaturated for 2’ at 96° and analyzed with 3100 Genetic Analyzer sequencer
(ABI PRISM-HITACHI).
Preparation of competent E. coli cells
50 ml of E.coli cells were grown at 37°C in 2XTY liquid broth to OD600 0.5. The bacteria
were immediately chilled in ice for at least 20’, then centrifuged at 4°C for 5’ at 1200 rpm. The
supernatant was discarded and the bacterial pellet resuspended in 5 ml of sterile TSS. The cells
were immediately used or stocked at -80°C for two months.
Bacterial transformation
A 100 μl vial of competent cells was incubated for 20’ with 5 μl of ligation reaction
mixture. Heat shock was applied at 42°C foe 1’15’’; after 2’ in ice, the bacteria were
resuspended in 1 ml of liquid 2XTY and allowed to grow for 1 hour. No antibiotic was added.
Bacteria were then plated on antibiotic-containing agar plates and grown O/N at 28-30°C.
Preparation of electrocompetent cells
For the preparation of electrocompetnt cells, the following protocol was applied:
 from an O/N culture of bacteria, 200 μl of culture was added to 200 ml of 2XTY liquid
broth at 37°C to OD600 0,8;
 the whole culture was splitted in 4 50ml-tubes, and chilled for 30’;
 centrifugation at 5000 rpm, at 4°C for 8’;
 the supernatant was discarded, and pellet was resuspended with 5 ml of glycerol buffer;
 glycerol buffer was added to 50 ml and the tubes were chilled for 10’;
 centrifugation at 5000 rpm, at 4°C for 10’;
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 the supernatant was discarded, the pellet resuspended with 5 ml of glycerol buffer and
the suspensions collected in two 50ml-tubes;
 glycerol buffer was added to 50 ml and the tubes were chilled for 10’;
 centrifugation at 5000 rpm, at 4°C for 10’;
 the supernatant was discarded, the pellet resuspended with 5 ml of glycerol buffer and
the suspensions collected in one 50ml-tubes;
 glycerol buffer was added to 50 ml and the tubes were chilled for 10’;
 centrifugation at 5000 rpm, at 4°C for 10’;
 the supernatant was discarded and the pellet resuspended with 125 μl of glycerol buffer
for every 100 ml of bacterial culture;
 cells were immediately used or stocked at -80°C for 2 months.
10 pg of purified pUC119 vector (Invitrogen) was used to test the efficiency of cells,
generally about 1010 transformed clones/μg DNA

Bacterial transformation of electrocompetent cells
The ligation mixture were purified and used to transform electrocompetent bacteria. A
Eppendorf 2510 electroporator were used. 1 μl of purified ligation product was added to one
aliquot of cells (35-40 μl), and chilled in ice for 30’’. The bacteria were transferred into a
cuvette (Eppendorf): after the electroporation cycle (at 1800 volts), the bacteria were
resuspended with 1ml of 2XTY, allowed to grow at 37°C for 1 hour and plated on antibiotic-
containing agar plates and grown at 28-30°C.
Preparation of bacteria for -80°C stock
The bacteria were collected and resuspended with a solution of 80% 2XTY and 20%
glycerol.
Protein electrophoresis on polyacrylamide gel and western blot
Protein samples, diluted 1:1 in loading buffer 2x for proteins, were loaded on 12%
polyacrylamide gel, composed by a stacking and running gel. The proteins were separated at 18-
20 mA.
Coomassie staining
The SDS-polyacrylamide gel was removed from the glass and stained with Coomassie
solution, under gentle shacking for 1 hour at 37°C. Then, Coomassie solution must be removed
(it can be reused many times) and the gel rinsed with destaining solution on a slow shaker for 6-
12 hours.
Western blot
Proteins were separated by SDS-PAGE and transferred onto nitrocellulose membrane
(Schleicher-Schuell) by semidry blotting using the Trans-Blot SD Transfer Cell (Biorad). The
membrane was treated as follows:
 blocked with MPRB 1 hour at RT (20°C);
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 primary antibody: mouse anti-FLAG 1:5000 (Sigma), mouse anti-His 1:5000 (Abcam),
mouse anti-SV5 mAb 1:2000 (1mg/ml); 1 hour at RT;
 two washes with PBST and two washes with PBS;
 secondary antibody: goat anti-mouse AP conjugated (Jackson Immunoresearch), 1 hour
at RT;
 two washes with PBST and two washes with PBS;
Immunocomplexes were revealed by adding the chromogenic substrate NBT-BCIP (Sigma)
in AP buffer, and the plate read at OD450.
Bradford protein assay
The following protocol was used:
 add 30 sample volumes of Bradford reagent (Sigma) to protein sample: mix the solution
and incubate at RT for 20’;
 make the “blank”, adding the Bradford reagent to the buffer used for the solubilization
of proteins;
 make a dilution series of BSA (bovine serum albumin, Sigma) in the range 50 ng-10μg;
 cool samples to RT and measure the absorbance at 562 nm;
 plot the average-blank corrected measurement for each standard vs. concentration. Use
the slope of this standard curve to estimate the protein concentration of the unknown
samples.
Expression of recombinant proteins
Clones were picked from agar plates and grown at 37° in 2 ml of 2XTY. At OD600 0.5, IPTG
0,2 mM was added to induce the production of the recombinant protein, allowing growth O/N
at 28°C.
To obtain the total fraction, 100 μl of bacterial culture were centrifuged at 5000 rpm for 5’,
the supernatant discarded, and the pellet resuspended with 50 μl of PBS.
To obtain the periplasmic fraction, the remaining bacterial broth were centrifuged at 5000
rpm for 5’, and the supernatant discarded. The pellet was resuspended in 1:10 of culture volume
of PPB, chilled in ice for 1 hour, vortexing every 10’. The mixture was centrifuged at 11000
rpm for 15’. The supernatant containing the periplasmic proteins (periplasmic fraction) was
collected.
Ewt, Kwt and glycine-mutant coils construction
All primers are reported in table 3.1.
Two pairs of primers were used to construct the Ewt and Kwt sequences: Kwt-sense/Kwt-
anti, and Ewt-sense/Ewt-anti. The sense and antisense primers were annealed together by their
complementary sequences; the resulting amplificates were cloned as BssHII/NheI (Kwt) and
EcoRI/HindIII (Ewt) fragments into the pω and pα vector respectively.
The glycine mutant coils (Emut, Kmut, Egly and Kgly) were generated with three
subsequent cycles of amplification, where the product of the previous amplification is the
template of the subsequent cycle. The templates for the first amplification were pα-Ewt and pω-
Kwt. The following combination of primers was used:
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- Emut: Emutgly-sense, Emutgly2-sense and E-EcoRI-sense (first, second and third PCR
amplification); E-HindIII-anti as antisense primer for all three cycles;
- Kmut: Kmutgly-sense, Kmutgly2-sense and K-BssHII-sense (first, second and third
PCR amplification); K-NheI-anti as antisense primer for all three cycles;
The first primer sense was replaced by Egly-sense and Kgly-sense for the construction of
Egly and Kgly coils respectively. Each final amplification step produced fragments with the
appropriate restriction sites at the ends: BssHII/NheI for K-coils, EcoRI/HindIII for E-coils. The
resulting amplificates were cloned into the pω and pα vector respectively.
Each vector was transformed in E. coli competent cells, and the bacteria plated onto plates
containing the antibiotic (chloramphenicol 34μg/ml for pω constructs, kanamycin 50μg/ml for 
pα constructs). After an incubation O/N at 30°C, the bacteria were picked, checked and stocked
at -80°C with 20% glycerol.
Preparation and transformation of pω-Kran library
To produce the Krandom fragments, three subsequent cycles of PCR were performed, using
the following combination of primers: Kran1-sense, Kmutgly2-sense and K-BssHII-sense (first,
second and third PCR amplification), and K-NheI-anti as antisense primer for all three cycles.
The template for the first amplification was pω-Kwt vector. Final amplification step produced
fragments with BssHII/NheI restriction endonucleases sites respectively at 5’ and 3’ ends.
pω vector (2 μg) and K random fragments (800 μg) were digested using BssHII and NheI
restriction endonuclease. After purification, they were ligated with T4 DNA ligase in a mixture
at a 1:4 ratio (number of molecules). The ligation was performed O/N at 16°C. The enzyme was
heat-inactivated at 60°C for 10’, and the ligation product was purified using NucleoTraP CR Kit
(Machery-Nagel) and resuspended in 20 μl water. The transformation into E. coli cells was
performed with the 2510 Electroporator (Eppendorf), by transforming 15-20 aliquots of
electrocompetent cells, each one with about 1 μl of DNA. After electroporation cells were
pooled, allowed to grow in 5 ml of 2XTY liquid broth for 1 hour at 37°C, and then plated onto 6
25cm2-plates with 34 μg/ml chloramphenicol. Dilution were plated onto a small plate with 34
μg/ml chloramphenicol to assess the size of the library. To verify the absence of contamination
for the subsequent PCA test, a little amount of bacteria was plated on plates containing 100
μg/ml ampicillin.
After 15 hour of incubation at 30°C, libraries were inspected by PCR harvested and stocked
in small aliquots at -80°C with 20% glycerol.
Preparation and transformation of pω-Krd library
Two pairs of degenerated primers were used to construct the K rational design sequences: K-
deg-sense and K-deg-anti. The sense primer shares a sequences with the complementary
antisense primer, that allows an assembly-PCR step. The produced fragments carried
BssHII/NheI restriction endonucleases sites, respectively at 5’ and 3’ ends.
pω vector (2 μg) and Krd fragments (800 μg) were digested using BssHII and NheI
restriction endonuclease. The same ligation-transformation procedure of pω-Kran library was
applied for this library.
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After electroporation cells were pooled and grown in 5 ml of 2XTY liquid broth, for 1 hour
at 37°C, and then plated onto 6 25cm2-plates with 34 μg/ml chloramphenicol. Dilution were
plated onto a small plate with chloramphenicol to assess the size of the library. To verify the
absence of contamination for the subsequent PCA test, a little amount of bacteria was plated on
plates containing 100 μg/ml ampicillin.
After 15 hour of incubation at 30°C, libraries were inspected by PCR, harvested and stocked
in small aliquots at -80°C with 20% glycerol.
PCA-validation of Ewt, Kwt and glycine-mutant coils.
The PCA was performed to test the interaction activity of the wild type and glycine-mutant
coils. DH5α were co-transformed as listed in the table.
DH5α carrying
vector:
Co-transformed with:
pα-Ewt
- pω-Kwt
- pω-Kgly
- pω-2.8
pω-Kwt
- pα-Egly
- pα-tTG
pω-Kmut - pα-Emut
Table 3.2 – The table shows the different combination of DH5α co-transformants cells.
After incubation for 1 hour at 37°C without selective pressure, the co-transformed cells were
plated onto 2XTY agar plates supplemented with 50 μg/ml kanamycin and 34 μg/ml
chloramphenicol, and incubated O/N at 30°C.
Single clones of each co-transformed bacteria were grown in 2XTY broth, supplemented
with 50 μg/ml kanamycin and 34 μg/ml chloramphenicol, at 37°C to OD600 0.5. Serial 1:10
dilutions of the original bacterial culture were done: 20 μl of 10-3, 10-4, 10-5, 10-6 and 10-7
dilutions were plated, obtaining spots with distinguishable single colonies, either onto 2xTY
agar plates supplemented with 50 μg/ml kanamycin and 34 μg/ml chloramphenicol for tittering,
or onto plates supplemented with increasing concentrations of ampicillin (50–100–200-400-
800-1200-1600 mg/ml) and 1 mM IPTG. The plates were incubated at 28°C for 48 hours.
The bacterial growth of each dilution was analyzed and compared in all the plates: the
comparison of the bacteria growth on agar plates allowed to assess the ratio “co-
transformed/interactors” for each ampicillin concentration. The results of the bacteria plated on
chloramphenicol/kanamycin plates represented 100% of growth. The data can be reported in a
graph.
PCA-validation of K random and K rational design coils.
Electrocompetent DH5α cells, carrying the vector pα-Ewt, were electroporated with 500 ng
of either pω-Kran or pω-Krd: the bacterial culture were equally plated onto a 25cm2-agar plate
supplemented with 50 μg/ml kanamycin and 34 μg/ml chloramphenicol, and onto 6 25cm2-agar
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plates supplemented with increasing concentrations of ampicillin (200-400-800-1200-2000-
3000 μg/ml) and 1 mM IPTG. The plates were incubated at 28°C for 48 hour. Dilutions were
also plated onto a small 2xTY agar plate (25cm2) containing kanamycin and chloramphenicol
for titering.
Selected bacteria, grown at the highest concentration of ampicillin, were picked, checked by
PCR and grown to OD600 0.5. Serial 1:10 dilutions of the bacterial culture were done: 20 μl of
10-3, 10-4, 10-5, 10-6 and 10-7 dilutions were plated obtaining spots with distinguishable single
colonies, either onto agar plates supplemented with 50 μg/ml kanamycin and 34 μg/ml
chloramphenicol for tittering, or onto plates supplemented with increasing concentrations of
ampicillin (200-400-800-1200-2000-3000 mg/ml) and 1 mM IPTG. The plates were incubated at
28°C for 48 hours.
The bacterial growth of each dilution was analyzed and compared in all the plates: the
comparison of the bacteria growth on agar plates allow to assess the ratio “co-
transformed/interactors” for each ampicillin concentration. The results of the bacteria plated on
chloramphenicol/kanamycin plates represent 100% of growth. The data can be reported in a
graph.
pMAL-ASC2 and pGEX expression vectors sub-cloning
The AscI endonuclease site of pMAL-ASC2 is compatible with the overhangs of BssHII site.
Therefore, the fragments Kwt, Kran 5.11, Kran 5.17, Krd F8 and Krd F26 were directly
subcloned as BssHII/HindIII fragments from the pω vectors into pMAL-ASC2 vector,
previously digested with AscI/NheI. Primers were designed to introduce the appropriate
restriction endonuclease sites at the ends of Ewt sequence: the pα-Ewt was amplified with E-
BssHII-sense and E-NheI-anti.
Fragments were digested with BssHII/NheI and subcloned into pMAL-ASC2 and pGEX
vectors, ligated, purified and transformed into E.coli competent cells. The obtained clones were
inspected by PCR and stocked at -80°C.
Production and purification of GST- and MBP-fusion proteins
Bacterial clones were grown in 100 ml of 2XTY liquid broth, added with 100 μg/ml
ampicillin, at 37°C to OD600 0.5; the expression of the recombinant protein was induced by
adding 0.2 mM IPTG, and grown O/N at 28°C. The next day, periplasmic fractions containing
the recombinant proteins were extracted as follows:
 the bacterial culture was centrifuged for 20’ at 4000 rpm (4°C), the supernatant
discarded and the pellet resuspended with 10 ml of lysis buffer/gram of bacteria;
 the mixture was incubated in ice, in gentle shaking, for 15’;
 the lysozime was added at the mixture, 400 μg/ml of lysate, and the solution was
incubate in ice, in gentle shaking, for 30’;
 DNAse (50-100 ug/mL of lysate), PMSF (1mM) and EDTA (1mM) were added to
lysate, and incubated in ice, in gentle agitation for 45’:
 Sonication (Bandelin Sonoplus) was performed: 3 cycles, 1-2 minutes for cycle;
 After centrifugation for 20’ at 11000 rpm, the supernatant was collected and filtered
with 0.45 μm filter.
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To purify recombinant proteins, amylose resin (NEB) for MBP-fusion proteins and
glutathione Sepharose (GE Helthcare) for GST-fusion proteins were used following the
instruction of the manufacturer to perform affinity chromatografy. Briefly:
MBP purification GST purification
Binding
1 ml of amylose resin was added to
the lysate, and incubated for 1 hour
in rotation
400 μl of glutathione sepharose was
added to the lysate, and incubated
for 1 hour in rotation;
Packing
The resin was packed in a 10 ml-
column, and extensively washed with
a solution of 20 mM TrisHCl pH 8.0,
500 mM NaCl
The resin was packed in a 10 ml-
column, and extensively washed
with PBST and PBS pH 8.0
Elution
The proteins were eluted with a
solution of 10 mM (Sigma) (0.5 ml
each elution)
The proteins were eluted with a
solution of 50mM GSH (Sigma),
100mM NaCl, in PBS (0.250 ml
each elution).
Each fraction were dialyzed O/N to PBS.
MBP- and GST-fusion proteins ELISA assay
The ELISA assay with purified proteins was performed as follows:
 purified GST proteins was diluted to 10 μg/ml in PBS and 100 μl were coated in ELISA
wells (Costar), O/N at 4°C;
 the wells were extensively washed with PBS and 120 μl of blocking solution (MPBS)
were added to each well, incubating at RT for 1 hour;
 purified MBP proteins were diluted 10 μg/ml in PBS, and added 100 μl to each well;
 extensive washes were performed with PBST and PBS;
 primary antibody: mouse anti-SV5, diluted 1:2000 in MPBS. 100 μl to each well, at RT
for 1 hour;
 extensive washes were performed with PBST and PBS;
 secondary antibody: goat anti-mouse HRP conjugated (Jackson Immunoresearch),
diluted 1:2000 in MPBS. 100 μl to each well, at RT for 1 hour;
 after extensive washing with PBST and PBS, the immunocomplexes were revealed with
the chromogenic substrate TMB (Sigma), and the plate read at OD450.
Preparation and transformation of pB scE-K library
Each coil was separately constructed and randomized.
Kinv-sense and Kinv-anti primers were used to construct the inverted K-coil. The sense and
antisense primers were annealed together by their complementary sequences; the amplified
fragment was BssHII/NheI cloned into the pω vector.
By using the pω-Kinv as template, two pairs of primers were used to produce the K inverted
and randomized fragments: K1-PCR-sense/K1-PCR-anti and K2-PCR-sense/K2-PCR-anti. Two
subsequent cycles were performed. The E randomized fragments were separately produced,
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performing three subsequent cycles of PCR amplification, and using only one antisense primer:
E1-PCR-sense, E-mutgly2-sense, E3-PCR-sense and E1-PCR-anti.
After purification of final PCR products, the library was created by assembling Kinv
randomized fragments with E randomized fragments. The assembly was performed using
specific cycles of PCR amplification:
 9 cycles with Kinv and E randomized fragments mixed at 1:1 ratio (number of
molecules): this step allowed the assortment of fragments and the assembly;
 21 cycles: using external primers (K2-PCR-sense /E1-PCR-anti), the single chain
sequences were re-amplified, and the restriction endonucleases sites were included at
the ends (BssHII/XmaI).
The scE-K library (320 μg) and the pB vector (1500 μg) were both digested with BssHII and
XmaI. After purification, they were mixed in a ligation mixture at a 1:3 ratio. The ligation was
performed O/N at 16°C, and purified using NucleoTraP CR Kit (Machery-Nagel) and
resuspended in 20 μl water. 15-20 aliquots of electrocompetent cells were transformed, each one
with about 1 μl of DNA. After electroporation cells were pooled and grown in 5 ml of 2XTY
liquid broth, for 1 hour at 37°C, and then plated onto 6 25cm2-plates with ampicillin 100μg/ml.
Dilution were plated onto a small plate with ampicillin to assess the size of the library.
After 15 hour of incubation at 30°C, the library was inspected by PCR, harvested and
stocked in small aliquots at -80°C with 20% glycerol.
Production and PEG-precipitation of phages
A small aliquot of bacterial stock of the library was grown into 10 ml of 2XTY, at 37°C to
OD600 0.5: ampicillin was added. In these conditions, the bacteria express the pilus necessary
for phage infection. Bacteria were infected with the helper phage, that carries all the genes
necessary for the phage replication: 10 μl of helper phage (109 viral particles/ml) were added
each 10 ml of bacterial culture. The infection was performed at 37°C for 45’. After
centrifugation at 4000 rpm for 10’, the supernatant was discarded, and the pellet resuspended in
10 ml of 2XTY broth added with ampicillin (the resistance of phagemid) and kanamycin (the
resistance of helper phage), to select the bacteria containing both the phagemid and the phage
genome. Bacteria were grown shaking O/N at 30°C, to produce recombinant phages. To collect
them, the bacterial broth was centrifuged at 7000 rpm for 20’ and the supernatant recovered.
1:5 volume of PEG-NaCl (20% NaCl, 2.5 M NaCl) was added to supernatant. The mixtures
was chilled for 45’, shaking by inversion every 10’, and then centrifuged at 7000 rpm for 20’ to
pellet the phages. The supernatant was discarded and the pellet resuspended in PBS.
Library selection with magnetic beads
The phages were produced, PEG-precipitated and resuspended in 250 μl of PBS (about 1012
phages). Phages were then incubated in a well of ELISA plates (Sarstedt), previously pre-
incubated with MPBS (the buffer used for the selection), to remove non-specific phages. The
phage solution was moved into another well, still pre-incubated with MPBS: this step was
repeated 10 times.
The phage solution was moved in a new well, previously pre-incubated with streptavidin
(New England Biolabs) 10 μg/ml, and blocked with MPBS at RT for 10’. The solution was
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moved into a new well, treated in the same way: this step was repeated 5 times. 250 μl of MPBS
and biotinylated caffeine (10 μg for the first round, 50 μg for the following rounds) were added.
To the phage solution: the mixture was incubated and gently shacked at RT for 1 hour.
Paramagnetic streptavidin-coated beads were added and shacked for 1 hour. After extensive
washes with PBS/0,1% Tween (PBST) and PBS (to remove all unbound and unspecific phages),
elution was performed incubating beads at RT for 30’ with a 100 ug/ml solution of caffeine
without linker nor biotin..
After this selection, 9 ml of DH5α at OD600nm 0.5 were infected with the recovered phages, at
37°C for 45’. Then, bacteria were centrifuged at 2500 rpm for 15’ (15°C), the supernatant
discarded, the pellet the resuspended with 1 ml of 2XTY broth and plated, allowing the growth
O/N at 37°C. The day after, bacteria were harvested and stocked at -80°C in glycerol. A small
aliquot was immediately let to grow in order to produce new phages for a second round of
selection. Four passages of selections were carried out, with increasing stringency of washing
steps.
Phage ELISA
The phage ELISA assays, by using the selected phage library, were performed as follow:
 coating: each well was incubated with 100 μl of coating solutions, containing the ligand
(see table 3.3), O/N at 4°C;
 blocking: after extensive washes with PBS, the wells were blocked with either 140 μl of
MPBS or PBS Tween 0.3%, at RT for 1 hour;
 phage incubation: after extensive washes with PBS, 50 μl of page solution and 50 ul of
blocking solution were added, at RT for 1 hour;
 extensive washes with PBST and PBS;
 secondary antibody: mouse antiM13 HRP conjugated (Amersham, Pharmacia) was
diluted 1:2000 in the blocking solution and added to the wells at RT for 1 hour.
 extensive washes with PBST and PBS;
 Immunocomplexes were revealed with the chromogenic substrate TMB (Sigma), and
the plate read at OD450.
Nunc Immobilizer™
Amino NUNC Plates
Sarstedt plates
Coating
solutions
10 g/mL of ligand solution in 100
mM pH 9.6 sodium carbonate buffer.
1) 10 g/mL of streptavidin solution
(New England Biolabs), diluted in
PBS. 100 μl each well, O/N at 4°C.
2) 20 g/mL of biotinylated ligand,
diluted in PBS. 100 μl each well, 1
hour and 30’ a RT.
Table 3.3 – Different coating solutions for Amino NUNC and Sarstedt plates.
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